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 Abstract 
A global estimate indicates that over 70 million heterosexual married couples live with 
the burden of infertility, and Nigeria accounts for about 30%. Although protocols exist, it 
appears there are no standardized treatment guidelines for practicing fertility experts in 
Nigeria. This study, therefore, aimed to determine which protocol provides a better 
outcome across a given population of infertile women in Nigeria as a method to move 
towards developing standardized treatment guidelines. The study was grounded using the 
Patient-Centered Care Treatment Model, and the method of inquiry was a retrospective, 
cross-sectional, quantitative, and nonexperimental technique, and the influence of the 
patient’s socioeconomic status, age, education, ethnicity, medical condition on treatment 
outcome were examined. A 3-year secondary dataset of assisted reproductive technology 
was collected from 10 fertility centers covering the 6 geographical zones of Nigeria. A 
sample size of 605 women, aged 20 to 50 years, was used in this study. Descriptive and 
nonparametric, Wilcoxon rank-sum, Kruskal-Wallis, and Pearson’s correlation tests 
statistical analysis were performed. The Wilcoxon rank-sum test showed a statistically 
significant difference between long protocol (Median 8) and short protocol (Median 4). 
Also, there were statistically significant differences between the number of oocytes and 
patients’ characteristics such as; age, education, socioeconomic status, medical condition, 
ethnicity, and religion, at p < 0.05. The result demonstrated that long protocol was 
superior to the short protocol in terms of number and quality of oocytes yielded across 
the study population. The study findings serve as a guide for practicing fertility experts in 
Nigeria with the view to improve fertility treatment outcomes in women.  
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Chapter 1: Introduction to the Study 
A full-term pregnancy is desired for many married couples worldwide. The 
presence of children binds families and marriages together in a certain culture, 
religion, and beliefs (Becker, Castrillo, Jackson, & Nashtigalle, 2016). In many 
African cultures, in particular, such beliefs are so strong that marriages that bear no 
fruit of a child, especially a male child, often withers without remedy, and such 
marriages are associated with polygamy (Okoroike, 2009). 
Although 75% of married couples achieve pregnancy naturally within the first 
6 months of living together, 90% of others accomplish the same feat within 12 
months, and another 10% and even more cannot become pregnant naturally despite 
numerous attempts of unprotected sex (Merviel et al., 2015). This 10% of married 
couples who cannot conceive naturally after 12 months are referred to as an infertile 
couple (National Institute for Health and Clinical Excellence, 2006). Infertility is of 
two types: primary and secondary infertility. It is referred to as primary infertility 
when the woman has not experienced conception before, and it is secondary infertility 
when the woman has experienced repeated pregnancies without success of carrying 
the pregnancy to term or live birth (Consineau, 2007; Mascarenhas, Flaxman, 
Boerma, & Vanderpoel, 2012). Consineau (2007) reported that the most diagnosed 
type of infertility worldwide is secondary infertility.  
The number of reported cases of infertility is increasingly high in both 
developed and developing countries, with the latter suffering more due to lack of 
modern technologies, treatment options, government policies, and adequate 
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knowledge. This is compounded by the difficulty of accessing or procuring treatment 
because of location (Carter et al., 2011). 
Infertility, as a condition, is now referred to as a severe public health issue of 
importance, as the burden has continued to increase worldwide (Mascarenhas et al., 
2012). The World Health Organization reported that infertility affects 15% of women 
of reproductive age globally. Approximately 60 to 169 million heterosexual couples 
worldwide experience infertility related issues, which implies that one out of every 10 
heterosexual couples suffers impotence (Ali, Ebraheem, & Mohamed, 2012; 
American Society for Reproductive Medicine [ASRM], 2015). 
The impact of infertility varies by country and region or continent in the range 
of 5 to 30% (Mascarenhas et al., 2012). In the United States, about 8.3 million 
married women are experiencing infertility (Boivin, Bunting, Collins, & Nygren, 
2007). This figure translates to 15% of married heterosexual couples having difficulty 
with achieving pregnancy (Resolve, 2013). The burden is higher in low-middle 
income countries, with more than 30% of heterosexual couples experiencing 
infertility issues (Ebomoyi & Adetoro 1990; Adetoro & Ebomoyi, 1999; Larsen, 
2000). 
Recent studies have debunked the misconception that the infertility burden 
exclusively affects women, showing that both sexes are significantly involved in 
infertility across nations and socio-economic status (Inhorn & Fakih, 2006). The 
cause of infertility issues stems equally from men and women; men account for 35% 
of cases seen, and women also account for 35% of cases, 20% is attributable to both 
male and female factors. Some other unexplained or idiopathic attributes account for 
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10% of cases seen worldwide (Mascarenhas et al., 2012). Some factors ranging from 
hormonal, lifestyle, medical, and structural are implicated in the cause or pathogenesis 
of infertility in men and women. 
The diagnosis of infertility can be devastating in women because such a 
diagnosis may change her orientation about life and may even result in fear of losing 
her marriage or living without a child should there not be any solution or difficulty 
accessing any form of existing intervention (Boivin et al., 2007).  
Modern approaches exist to address infertility in the form of advanced 
technology, such as pre genetic diagnosis and screening, intrauterine insemination, in 
vitro fertilization (IVF), and intracytoplasmatic injection, which have restored 
marriages and brought relief and completeness to couples worldwide (Lundborg, 
Plug, & Rastmussen, 2017; Okwelogu, Azuike, Ikechebelu, & Nnebue, 2012).  
IVF is the most prominent approach or intervention for infertility treatment. 
Two treatment protocols exist for IVF: (a) short antagonist protocol and (b) long 
agonist protocol, and the course of treatment using either of these protocols is 2 to 4 
weeks (Carter et al., 2011; Okwelogu et al., 2012). The procedure requires using 
hormonal medications for down-regulation, stimulating the ovaries, collecting 
matured follicles (ova) from the ovaries, mixing the egg and washed sperm cells 
(viable sperms) to fertilize and to form embryos and transferring embryo(s) into the 
uterus (American Society for Reproductive Technique, 2015; Lundborg et al., 2017). 
The nidation or early implantation of the fetus is the measure of a successful transfer 
of the embryo, which often determines the outcome of clinical pregnancy in the IVF 
procedure. This modern technology has restored homes and mended marriages on the 
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verge of collapse, though it is challenging to procure and expensive where it is 
available (Carter et al., 2011).  
The study focused on Nigerian women and how factors such as religion, 
cultural beliefs, geographical location, ethnicity, and educational level interplay with 
her decision to seek early help in the form of IVF treatment using agonist-antagonist 
protocols. The knowledge of the dynamics of these factors can help to influence 
government policies that can promote awareness, attitude, and behavioral practices of 
infertile women to seek early treatment intervention when diagnosed with infertility. 
Besides, the knowledge can help fertility physicians as to which treatment protocol to 
apply at any given situation. 
Background of the Study 
There is limited literature on the prevalence of infertility in low-middle 
income countries. A 1-year prevalence study on infertility in low-middle income 
countries in sub-Saharan Africa reported showing the variation in prevalence of 
infertility by countries from the range of 6.9% to as high as 50%; Gambia 9%, Ghana 
11.8%, and Ethiopia 21.8%, and in Nigeria, the prevalence is 30 to 50% (Boivin et al., 
2007; Sherrod, 2004). The significant regional differences in the prevalence as 
reported were due to variations in cultures, beliefs, SES, environmental influence, and 
ethnic diversity (Adetoro & Ebomoyi, 1999; Ebomoyi & Adetoro, 1990; Larsen, 
2000). A search of the literature, however, revealed a dearth of information on fertility 
treatment and the determinants of help-seeking behavior of infertile women in 
Nigeria. Several studies have compared existing different ovarian stimulation 
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protocols for IVF (Carter et al., 2011; Okwelogu et al., 2012), but there is no research 
yet on the Nigerian situation.  
The two existing IVF treatment protocols that were comparatively studied are 
long agonist and short antagonist protocols using gonadotropin-releasing hormones 
(GnRH). According to Toftager et al. (2016), GnRH agonist protocol and  GnRH 
antagonist protocol are similar in cumulative live birth rates, although more oocytes 
were collected in the agonist protocol. Toftager et al. recommended the enhancement 
of embryo culture, thawing and freezing approaches, and elective single embryo 
transfer. 
Sudewo and Halim (2016) recommended the use of the antagonist protocol, 
which seems to be less of an adverse effect than agonist protocol in terms of the 
outcome of severe ovarian hyperstimulation syndrome (OHSS). However, both 
ovarian stimulation protocols have comparable efficacy in IVF outcomes (Sudewo & 
Halim, 2016). 
Long agonist protocol instead of short antagonist protocol is recommended 
because it yields a better outcome of quality oocytes (Sudewo & Halim, 2016). The 
disadvantages of long agonist protocol are higher gonadotropin consumption and 
longer length of stimulation. However, the outcomes are comparable between all 
protocols (Dakhly, Bayoumi, & Gad Allah, 2016). 
According to Dakhly et al. (2016), short antagonist protocol should be the 
recommended protocol for females less than 40 years, whether she is a poor or good 
responder to IVF treatment. A fixed gonadotrophin dose should be considered to 
prevent the risk of OHSS and other unexpected complications. 
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Toftager et al. (2016) conducted research that showed the rates of nidation and 
pregnancy per IVF cycle using long agonist and short antagonist protocol, as 
comparable in poor responders to stimulations in IVF. They recommended that the 
treatment of poor responders be re-evaluated regarding the likely contribution of age 
and the influence of lifestyle changes and other determinants of outcomes (Toftager et 
al, 2016). The reevaluation should also include consideration for bespoke ovarian 
stimulation, screening of blastocyst before the transfer, and consecutive IVF cycles 
(Ali et al., 2012). 
A short antagonist protocol produces more top-quality embryos than the long 
agonist protocol (Aslih, Ellenbogen, Michaelis, Samara, & Shalom-Paz, 2015). 
According to Aslih et al. (2015), endometrial receptivity of embryos is regulated by 
the modulatory effect of estrogen (E2) and progesterone (P), and the ratio of 
progesterone and estrogen can be used to estimate the likelihood of pregnancy 
outcome. 
Spremović-Radjenović et al. (2015) carried out a randomized controlled trial 
on a large scale to assess available IVF treatment protocols. They discovered that the 
available protocols for stimulating the ovaries are inadequate and still a challenge 
mainly because fecundity decreases with age, especially in women (Spremović-
Radjenović et al., 2015). 
Gizzo et al. (2014) reported that larger doses of progesterone are better than 
lower doses when considering high pregnancy rates. Gizzo et al. indicated that E2 
supplementation is better in the case of short antagonist protocol and recommended 
this in every protocol when E2 reaches max < 5 nmol/l and endometrial thickness 
7 
 
< 10 mm. However, they explained the need for further investigation of the actual 
benefit of E2 supplementation, which remains debatable (Gizzo et al., 2014). 
Short antagonist protocol is more suited for patients who respond poorly to 
stimulation. The long protocol does not favor these categories of patients. However, 
the long microdose protocol is comparable to the short antagonist protocol (Kdous, 
Elabed, Zhioua, & Zhioua, 2014). 
Xiao, Chang, and Chen (2013) recommended long agonist protocol over 
antagonist protocol because the antagonist protocol produces fewer matured and 
quality follicles to decrease estrogen level and thin endometrium when compared with 
long agonist protocol. However, cycle cancellation and pregnancy outcomes were 
similar.  
Problem Statement 
The problem is that there is no standard infertility treatment protocol guideline 
for infertile women seeking intervention in Nigeria. The lack of this standard has led 
fertility experts in Nigeria to apply any treatment protocol to treat infertile women 
desiring conception, and there is little or no information on how patient characteristics 
influence the outcome of fertility treatment. 
Generally, fertility treatment requires using hormonal medications to stimulate 
the ovary and generating matured follicles, harvesting eggs, and mixing the eggs in a 
specialized test tube with viable sperm cells for fertilization into embryos. These 
embryos are subsequently transferred back into the woman’s uterus using a special 
catheter under an ultrasound machine. This procedure is referred to as IVF. More than 
70 million married women worldwide are unable to conceive and are living with 
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infertility; the majority of them reside in low-middle income countries (Boivin et al., 
2007; Mascarenhas et al., 2012). Sub-Saharan Africa, especially Nigeria, South Asia, 
Middle East, and North Africa were reported to have the highest prevalence of 
infertility (Mascarenhas et al., 2012013). 
The global negative impact of infertility is on the rise worldwide, and Nigeria 
is no exception, with a high infertility prevalence rate of 30.3% (Adetoro & Ebomoyi, 
1991; Dattijo, Andreadis, Aminu, Umar, & Black, 2016; Ikechebelu et al., 2016). 
Given the value placed on having children and culture in Nigeria, women or couples 
without children as a result of infertility are bound to face social and psychological 
consequences, such as emotional stress, stigmatization, ostracism, economic loss, and 
mental stress (Consineau, 2007; Okoroike, 2009). According to Cousineau, 2007; 
Ikechebelu et al., 2016) report, couples facing infertility are at risk of sexually 
transmitted diseases, divorce, and marital instability. 
However, there is a solution for infertility using advanced assisted 
reproductive technologies (ART; e.g., IVF). This technology has been in existence 
since 1970 and has helped couples to complete families (Altmäe, Hovatta, Salumets, 
& Stavreus-Ever, 2011; Shrestha, La, & Feng, 2015). In a report completed for the 
Human Fertilisation and Embryology Authority, Cheshire (2013) noted that the new 
IVF technology required to address this challenge is scantly available and expensive 
in Nigeria and other developing countries. IVF uses the principle of controlled 
ovarian hyperstimulation (COH) of the ovaries with GnRH. The use of GnRH defined 
the protocol as either long agonist or short antagonist protocol (Altmäe et al., 2011). 
Several modifications to COH protocols have also evolved to date (Orvieto, 2015; 
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Toftager et al., 2016). These protocols are assessed based on the number of matured 
follicles generated, which directly correlates with successful conception rates and 
adverse events (e.g., OHSS) following COH stimulation in patients receiving IVF 
treatment (Hohmann, Macklon, & Fauser, 2003).  
Specific reasons for using or adopting a COH protocol may range from 
patient’s poor ovarian response (Okoroike, 2009; Venetis, 2014), age, disease 
conditions (e.g., polycystic ovary syndrome), SES, treatment duration, previous IVF 
treatment, cost of IVF, knowledge of protocols, treatment outcome, and safety 
consideration (Al-Inany & Aboulghar, 2002; Bosch et al., 2010; Murber, Fancsovits, 
Ledó, Gilán, & Urbancsek, 2009; Orvieto et al., 2009; Oudendijk, Yarde, Eijkemans, 
Broekmans, & Broer, 2012). 
According to Lai et al. (2013), the exact impact of these protocols on 
treatment outcomes has not been established and has remained controversial. Merviel 
et al. (2015) argued that no clear guideline currently exists for the COH treatment 
protocol in IVF despite several studies comparing COH treatment protocols. 
In Nigeria, the experience may differ, as no researcher has looked at which of 
these COH treatment protocols is better regarding treatment outcomes following the 
IVF procedure and the determinants of these outcomes. Besides, seeking treatment 
behavior is determined by patient characteristics, such as beliefs, gender, education, 
ethnicity, and SES, and no study has yet addressed the impact of these factors vis-à-
vis treatment-seeking behavior and treatment outcome. 
Hence, there is a need to study the relationships between these variables to 
determine which treatment protocol is most suitable and cost-effective to adopt for 
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Nigeria and other developing countries. Similarly, it is expected that such a protocol 
can positively influence the development of an interventional program that can 
reverse the negative experience of infertile women or couples in Nigeria. 
Purpose of the Study 
This study aimed at establishing the IVF treatment protocol that is most 
suitable for the majority of infertile women in Nigeria. Patient characteristics, age, 
medical conditions (e.g., PCOS), SES, education, ethnicity, and other factors such as 
duration of treatment and safety consideration were also examined. Secondary data 
from 10 existing fertility treatment centers in five states across Nigeria, where IVF 
services are being offered (i.e., Abuja, Port Harcourt, Enugu, Jos, and Lagos) were 
used. These five states cover Nigeria’s capital city, South-South, South-East, North-
Central, and South-West, respectively. This study examined the outcome between 
long agonist and short antagonist treatment protocols used in these centers.  
Research Questions 
The research questions for this study were as follows: 
Research Question RQ1: What is the relationship between types of fertility 
treatment protocol and treatment outcome? 
H01: There is no significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
H11: There is a significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
RQ2: Do patient characteristics (age, education, SES, medical condition, 
ethnicity, religion) influence the outcome of fertility treatment protocol? 
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H02: Patient characteristics have no significant influence on the outcome of 
the fertility treatment protocol. 
H12: Patient characteristics have a significant influence on the outcome of the 
fertility treatment protocol. 
Conceptual Framework 
A theoretical or conceptual framework is composed of specific constructs, 
concepts, and propositions that guide and provide direction on the expectation of 
research (Fawcett & Garity, 2009; Glanz, 2002). The theoretical foundation for this 
research was grounded by the patient-centered care treatment model (PCCTM).  
According to the Institute of Medicine (2001), PCCTM is an intervention that 
supports, respects, and responds to patients’ characteristics, needs, and values at all 
levels of treatment decisions given the expected outcome. This conceptual model was 
developed by healthcare professionals in the 1980s and has been widely applied to 
examine treatment protocols and algorithms of disease intervention (Danga, 2018). 
This model has gained popularity in understanding fertility treatment and outcomes 
(Duthie et al., 2017). In 2014, Duncan et al. used PCCTM for infertility treatment to 
explain the dimensions of fertility treatment, outcome (effectiveness and potential 
risk), financial cost, and patient characteristics. 
The concept of effectiveness in this model is defined as the probability that 
any chosen treatment protocol will yield the expected positive outcome when applied 
across the population of infertile women seeking fertility treatment. The inherent risk 
in this model explains the possibility of adverse events that may result from treatment 
(e.g., OHSS). The financial cost of treatment in this model explains the effect of 
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financial cost on treatment protocol and prices for different options, and patient 
characteristics stressed the impact on age, education, ethnicity, medical condition, 
SES. 
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Figure 1. The conceptual framework for patient-centered fertility treatment 
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Definition of Key Terms 
Antimullerian hormone: An inhibitory glycoprotein hormone that plays a 
significant role in folliculogenesis.  
Assisted reproductive technique: The technique or procedure, such as in-vitro 
fertilization, intrauterine insemination, and surrogacy, used for fertility treatment to 
achieve pregnancy outcome. 
Control ovarian hyperstimulation: A process used in ART to stimulate the 
ovarian follicles in a fashionable manner using hormonal medications to generate 
multiple follicles for the induction of ovulation.  
Follicle-stimulating hormone: A natural hormone that is produced by the cells 
of the anterior lobe of the pituitary gland; it promotes the development of ova in 
women and sperm in men. 
In vitro fertilization: The process of stimulating the ovary with hormonal 
medication to grow ovarian follicles to maturity, harvesting the eggs, and 
inseminating it with viable sperm cells in a cultured tissue dish to fertilize, and then 
transferring the generated embryo(s) into the uterus. 
Luteinizing hormone: A gonadotrophic hormone of the anterior pituitary lobe 
that triggers ovulation at its peak level in females and facilitates the development of 
corpus luteum. In a male, it helps to promote testosterone by stimulating Leydig cells.   
Ovarian hyperstimulation syndrome: A drug-induced condition that may result 
during ART following stimulation of the ovary with exogenous hormonal medication. 
Most of the time, the situation is mild but could be severe.  
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Polycystic ovarian syndrome: A combination of symptoms that result from 
elevated male androgen hormones in women. 
Socioeconomic status: This is a measure of a person’s, family’s, income, 
education, occupational, work experience, and social position in a society using 
economic and sociological indices.  
Assumptions 
Several assumptions were made for this study. Given the nature of this study, 
it was assumed that all the fertility hospitals used for this study met standards of the 
hospital accreditation committee of the state or federal government of Nigeria and 
were licensed to render fertility treatment. It was also assumed that the facilities that 
offer such treatments were ISO-9001:2015 certified by the Standard Organization of 
Nigeria. The Association of Fertility and Reproductive Health of Nigeria is a 
registered professional organization recognized by law to regulate the practice of 
fertility professionals in Nigeria. Hence, all stakeholders in the fertility facilities used 
for this study were registered members of the Association of Fertility and 
Reproductive Health of Nigeria. 
Likewise, it was assumed that the infertile women who were treated in these 
hospitals were appropriately diagnosed using all the diagnostic tools and fertility 
scores before embarking on treatment. Additionally, the language of communication 
between the women and doctors was English.  
Scope and Delimitations 
The data of all ART procedures conducted between 2015 and 2017 in the 
entire 10 fertility treatment centers across the five states in Nigeria were collected. 
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Only women aged 20 to 50 years were considered because the median reported age 
that is safe for most infertile women seeking help is 23 years (Frankfort-Nachmias & 
Nachmias, 2008). Such eligible women were diagnosed as infertile by a qualified 
medical doctor considering all the parameters from her history, complaints, physical 
examination, ultrasound scan, and laboratory results (FSH, LH, prolactin, AMH, 
progesterone, estrogen). Only women who had successful egg collection were 
considered. The educational level, SES, and sociodemographics of all qualified 
women who had IVF procedures up until the point of egg collection are discussed and 
examined. Two treatment protocols were considered in this study, long and short 
protocol, and the measure of successful treatment outcome was the number of eggs 
collected.  
All women who had attended the named fertility clinics without full 
evaluation were excluded from this study. Similarly, women who had started 
treatment after evaluation but had canceled procedures along the line, as well as egg 
recipient cycles, were also exempted from this study. 
Limitations 
Limitations were anticipated. First and foremost was that the research work 
required moving around the six geographic zones of Nigeria and visiting a total of 15 
fertility centers. Only 10 centers were successfully visited because of poor logistical 
systems and infrastructure in some states or geographic zone. Secondly, the study 
required the use of secondary data of infertile couples who had accessed treatment in 
those fertility centers. The implication is that some relevant information was not 
captured in an organized pattern. Thirdly, some of these fertility centers were handled 
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by medical officers who lacked adequate skills in IVF procedure; the effect was on 
the quality of the decision as to which treatment protocol could best suit a case of 
infertility. 
Significance of the Study 
The educational and SES of residents of these five states were classified into 
high, middle, and lower, with the high class comprising of professionals (i.e., doctors, 
lawyers, engineers, and accountants), politicians, and nurses. The middle class 
included bankers, teachers, journalists, and entrepreneurs, while lower-class referred 
to the skilled (e.g., technicians, mechanics, carpenters), semiskilled, and unskilled 
workers, and petty traders. In Nigeria, like most other countries of the developing 
world, the class determines the income, but the city of residence also affects the SES 
(e.g., the cost of living is believed to be generally higher in Port-Harcourt, an oil-rich 
state, than Kebbi state, an agrarian state). These factors played a role in residents 
seeking fertility treatment and outcomes. The second part of this study was the 
stimulation protocols used in IVF treatment. Although several scholarly reports 
compared the results of various stimulation protocols in IVF treatment, none of these 
reports looked at Africa’s most populous nation, Nigeria, and a literature search of 
“early online’’ articles revealed no such pending reports. This study was the first in 
this area in Nigeria that has attempted to solve this puzzle. 
Moreover, there was a need to conduct an audit of the treatment outcome(s) of 
stimulation protocols, whereby fertility specialists are informed of the effectiveness of 
protocols employed and infertility conditions treated. The result of this study revealed 
the required information, which is nonexistent in Nigeria. 
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The Implications for Social Change 
The positive social change of this study is that the research findings can serve 
as a guide for practicing fertility specialists or intending specialists within or outside 
Nigeria. The evidence-based rationale has been provided to initiate treatment on an 
individual patient basis and the implications of deciding which treatment protocol 
befits each who presents at the fertility clinic. Likewise, findings have provided the 
foundation to apply a particular protocol across a defined population with an 
understanding of treatment outcomes of the two protocols. 
Summary 
Pregnancy is the desired expectation of many married couples, especially in 
Africa, where children are cherished and valued (Okoroike, 2009). In some cultures in 
Africa, an infertile woman is not given her due respect and entitlements in marriage if 
she has not given birth to a male child. In these situations, her marriage is threatened 
by her husband taking another wife, or she may face divorce. Infertility is when 
heterosexual couples living together and have regular unprotected sex for 1 year but 
fail to achieve a natural pregnancy.  
Infertile women or couples who experience infertility require help after the 
diagnosis to become pregnant. The diagnosis could either be primary infertility or 
secondary infertility. The former is when the woman has not given birth before, and 
secondary infertility is when a woman had given birth previously and failed 
subsequently to become pregnant again. Secondary infertility is the most commonly 
diagnosed type of infertility experienced by most infertile women (National Institute 
for Health and Clinical Excellence, 2004).  
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Infertility issues are recognized as an essential public health issue, with over 
70 million heterosexual married couples living with this condition worldwide (Dattijo 
et al., 2016; Ikechebelu et al., 2016). The majority of these couples live in African 
countries, of which Nigeria is one. The high number of infertile women on the 
African continent has been attributed to differences in lifestyle, culture, beliefs, and 
poverty, among others. Based on the available data, the prevalence of infertility varies 
by regions; sub-Saharan Africa ranges from 9% in the Gambia to 11.8% in Ghana and 
21% in Ethiopia, and as high as 20% to 30% in Nigeria (Boivin et al., 2007; Ebomoyi 
& Adetoro, 1999). 
The high number of infertile women in Nigeria is very alarming, despite the 
limited data. It is a general belief by most infertile couples in Nigeria that access to 
IVF is very prohibitive and is for the rich. This may not be entirely true, as several 
factors interplay to influence the help-seeking behavior of infertile women. 
Consequently, there was a need to assess these factors and available treatment 
protocols accurately.  
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Chapter 2: Literature Review  
There is a dearth of information on infertility treatment and factors that 
influence fertility treatment outcomes in Nigeria. Therefore, this study was designed 
to answer questions regarding infertility treatment and the behavior of infertile 
women towards early treatment in Nigeria. The overall aim of this study was to assess 
the factors affecting treatment outcomes and the choice of IVF treatment protocol by 
the provider. The results of this study provide the basis for designing an intervention 
that influences the choice of protocol for fertility treatment in Nigeria.  
The relevant literature on infertility in Nigeria are reviewed in this chapter. 
Also reviewed is the research on causative factors, treatment protocols, nondrug 
treatment of infertility, barriers to treatment-seeking behavior of women with 
infertility, as well as the current trend in infertility treatment. There are nine sections 
in this chapter, which ends with a summary. 
Literature Search Strategy 
There are few research articles on some aspects of the study, especially recent 
publications and those spanning the past 10 to 20 years. I found a few articles using 
Walden Library as my primary source of peer-reviewed articles, scholarly 
publications, dissertations, and electronic databases; ProQuest and PubMed were the 
major electronic databases used for the literature search. Fertility-related publications 
were identified with keywords such as infertility, infertility treatment protocols, 
determinants of infertility treatment, help-seeking behavior, and Nigeria. 
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Global Studies and Sub-Saharan Africa, Nigeria 
Infertility, as a health challenge, initially receives little or no attention in some 
societies of the world because of cultural beliefs and religious practices (Van Belen & 
Inhorn, 2002). Research in this area was limited as a result of the lack of data and the 
failure of those affected to declare infertility status (Adegbola, 2013). Infertility is not 
seen as a contagious disease or illness that affects the population but only individuals 
(Van Balen & Inhorn, 2002). The issues of nondisclosure and religious and cultural 
beliefs leading to a high prevalence of infertility were reported to be strongly 
associated with the developing non-Western countries, especially in sub-Saharan 
Africa. 
Infertility is an issue in all the countries of the world. One in every 10 couples 
suffers infertility-related issues caused by either the male or female factor globally 
(Adegbola, 2013). This reported statistic may be more because of under disclosure 
due to fear of stigmatization and failure to seek help (Van Balen, 2002).  
Hammerli, Znoj, and Barth (2009) noted that the prevalence rate of infertility 
in the United States was 11 to 18%, while that of Africa was as high as 30%. This 
finding implies that the problem of infertility is high in sub-Saharan Africa. Carter et 
al. (2011) and Hammerli et al. (2009) reported that infertile women are prone to 
anxiety, depression, and stress that could result in other illnesses if not properly 
treated. Therefore, infertility is a public health problem that needs to be addressed in 
every society. The prevalence of infertility can be reduced through an all-inclusive 
educational program that increases awareness and strengthens attitudinal and 
behavioral changes towards infertility treatment (Ali et al., 2012)  
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Two types of infertility exist, namely, primary and secondary infertility. 
Primary infertility is the nonachievement of conception by the couple that has resulted 
in a live birth, while secondary infertility occurs when couples find it difficult to 
achieve conception after a previous live birth or any difficulty with achieving term 
pregnancy (Schmidts & Munster, 1995).  
The length of infertility varies irrespective of the type. Conkling (2003) 
reported that the probability of heterosexual couples living under the same roof, 
having regular unprotected sex, and becoming pregnant within 1 month is between 20 
to 30%. Sixty to 75% of these couples will become pregnant by the sixth month, and 
75 to 90% will be pregnant by 12 to 18 months (Conkling, 2003). About 40 to 60% 
will become pregnant in the second year of trying (Dunson, Baird, & Columbo, 
2004).  
The duration of infertility is a critical prognostic factor providing information 
on the severity of the condition and the level of intervention that may be required 
(Smith, Pfeifer, & Collins, 2003). The longer the length of infertility experienced by a 
couple, the less likely it is to have a positive outcome following the intervention. 
Those with less than 3 years of infertility have a better chance to conceive than those 
living with this condition for 3 years and more (Smith et al., 2003). Sixty percent of 
couples with secondary infertility achieve pregnancy within 3 years of waiting 
compared to 40% with primary infertility who will wait likewise to achieve the same 
feat (White, McQuillan, & Greil, 2006). 
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Causative Factors in Infertility 
There are known and unknown causes of infertility in men and women 
worldwide. About 35 to 40% is attributed to female-related causes, and a similar 
proportion is also due to male-related causes (Conkling, 2003). The remaining 20 to 
30% are due to idiopathic, primary, or unknown causes (Conkling, 2003). The female 
known causative factors are old age; poor egg quality; hormonal imbalance; reduced 
ovarian reserve; blocked tubes; uterine fibroids; history of uterine surgeries like 
cesarean sections, myomectomy, and salpingectomy; repeated miscarriages; pelvic 
inflammatory disease; postpartum infection; abortion; sexually transmitted diseases; 
and other surgeries like appendectomies and cystectomy (Klein & Sauer, 2001). Male 
infertility is a function of sperm quality and quantity regarding count, motility, and 
morphology (American Society of Reproductive Medicine, 2015a; Debrovner & 
Debrovner, 2002; Klein & Sauer, 2001). 
Unexplained infertility occurs when couples still experience difficulty in 
achieving pregnancy despite standard laboratory and clinical findings. These can 
include normal FSH, LH, AMH, and prolactin levels, patent fallopian tubes, healthy 
endometrium, regular ovulation, and good quality semen (Speroff, Glass, & Kase, 
1999). 
Age 
The ability to get pregnant declines as age increases. This relationship between 
age and fertility is more pronounced in females. Age is the most influential and most 
common causative factor in female infertility. One in seven couples aged 35 years 
suffer infertility (Faitt-Weller, 2001). This rate rises to 1 in 5 among couples aged 40 
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and above (Faitt-Weller, 2001). Older females have more difficulty trying to 
conceive, and they are more likely to have recurrent miscarriages, stillbirths, 
underweight babies, preterm babies, babies with genetic disorders like Down 
syndrome, and placental complications (Adegbola, 2013; Kelly-Weeder & O’Connor, 
2006). More than 50% of older women have miscarriages (Kelly-Weeder & 
O’Connor, 2006). Age is a known and consistent factor in female infertility 
worldwide (ASRM, 2006). Males are also affected by age-related infertility caused by 
hormonal imbalances, sperm conducting system blockages, varicocele, erectile 
dysfunction, loss of coital power, and poor sperm quality as they age above 40 years 
(ASRM, 2006; Clavey, 2003; Rochebrochard & Thonneau, 2003).  
Lifestyle 
Certain social, behavioral practices or lifestyles are the reason for infertility in 
both men and women. These practices or lifestyles include smoking and excessive 
intake of alcohol, which negatively impact the overall sperm quality, count, 
morphology, and motility in males (Macaluso et al., 2010). According to Akhter and 
Jebunnaher (2012) as well as Kelly-Weeder and O’Connors (2006), obesity is 
associated with higher levels of estrogen, which has a contraceptive effect, resulting 
in miscarriages, menstrual disorders, anovulation, and poor pregnancy outcome. On 
the other hand, underweight is also associated with reduced estrogen, leading to 
irregular menstrual cycles (Akhter & Jebunnaher, 2012). Women who are obese with 
body mass index (BMI) of higher than 25 kg/m
2
 experience infertility twice as long to 
achieve pregnancy than those with healthy BMI (Hassan & Killick, 2005).  
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Stress, environmental toxins, substance abuse, and insomnia also contribute to 
infertility (Glenville, 2000). The use of some types of vaginal lubricants has a lethal 
effect on sperm cells and sperm motility, thereby reducing the chances of conception 
(Kutteh, Chao, Ritter, & Byrd, 1996). The lack of knowledge on when is the most 
fertile period for couples to time intercourse is also a factor in infertility (Bowers, 
2003; Devine, 2003; Neumann, 2003). 
Women who consume up to 7 grams or more of caffeine monthly are less 
likely to become pregnant than women who do not (Hakim, Gray & Zacur, 1998). 
Increased caffeine consumption raises the risk of endometriosis and tubal problems, 
which are associated with infertility (Neumann, 2003). 
Pelvic Inflammatory Disease 
Pelvic inflammatory disease (PID) is a common type of infection in women 
generally. PID is defined as the inflammatory disease of the pelvic organs due to 
infection. Sexually transmitted diseases account for 70% of PID cases (Adegbola, 
2013). This infection goes unnoticed in some women until such a time when it has 
caused harm to the pelvic organs, leading to infertility (Adegbola, 2013). This type of 
infertility is often considered as unexplained infertility. 
Chlamydia and Neisseria gonorrhea infections are transmissible through sex, 
and these infections often lead to PID. Any untreated infection can always develop 
into PID in women if not adequately treated (Kelley-Weeder & O’Connor, 2006). The 
CDC (2013) reported that over 1 million women in the United States are diagnosed 
with PID annually, out of which more than 100,000 end up with infertility issues. 
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Several studies have shown the association between infertility in women and 
the history of sexually transmitted diseases (STD) and PID. The number of diagnosed 
STDs is on the increase annually (Macaluso et al., 2010). Many of these STDs show 
no symptoms in some women until such a time that complications start to manifest. 
Black women are eight times more at risk of contracting infections involving 
chlamydia and gonorrhea, leading to STDs than White women. STDs can lead to 
tubal scarring and intramural tubal infection-causing infertility (Kelley-Weeder & 
O’Connor, 2006; Macaluso et al., 2010). 
Culture 
Culture is the way of life of people. There are cultural differences between 
different ethnicities across the world. Some cultural practices affect infertility in both 
sexes, especially when it borders on childbearing (Brown, 2001; Rochebrochard & 
Thonneau, 2003). For instance, it is normal for couples to agree to postpone 
childbearing for years after marriage for no significant reason in Western cultures 
(e.g., the United Kingdom, Canada, and the United States), but this arrangement is 
almost not acceptable in Africa, especially in Nigeria where delayed pregnancy is 
undesirable (Adegbola, 2013; Rochebrochard & Thonneau, 2003). 
Socioeconomic and Sociodemographic Factors in Infertility  
The number of infertile women is increasing rapidly. The 2002 National 
Survey of Family Growth (as cited in Chandra, Martinez, Mosher, Abma, & Jones, 
2005) pointed out that the prevalence of infertility among African American women is 
10.4%, 6.4% in White women, and 7% in Hispanic women in the United States.  
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Educational level is associated with infertility in women. Women with lower 
educational levels were reported to be less fertile than those with higher degrees 
(ASRM, 2016). Chinese women also were reported to significantly access fertility 
treatment services due to their high educational level and income (Jain, 2006).   
Access to infertility treatment is expensive worldwide, and most health 
maintenance organizations and insurance companies do not cover for it. Hence, out-
of-pocket treatment is often an alternative considered by those needing treatment. In 
the US, those who are highly educated and wealthy White infertile women are more 
likely to have access to fertility treatment than African American Women (Jain, 
2006).  
Infertility Treatment 
Klein and Sauer (2001) defined infertility treatment as an intervention strategy 
that helps infertile women to achieve pregnancy through assisted reproductive 
technology. The options for fertility treatment include treating all identifiable 
conditions in the couple that could inhibit conception, such as treating poor sperm 
quality, treating infection, surgical removal of blockages in fallopian tubes, 
myomectomy, correcting hormonal imbalance, enhancing cervical mucus, and 
utilizing treatment approaches like timed intercourse, intrauterine insemination, in-
vitro fertilization, and more modern ART called intracytoplasmic sperm injection 
(Simonsen, Baksh, & Stanford, 2012). 
Timed intercourse is a non-invasive approach that requires the use of 
medicines such as clomiphene or letrozole to stimulate the ovaries to maturity 
indirectly and, after that, induce ovulation with human chorionic gonadotrophins. 
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Timed intercourse happens within 36 hours post-induction of ovulation. This 
approach is considered for infertile women with an anovulatory problem. 
Intrauterine insemination is also a non-invasive treatment approach that is 
targeted at washing the sperm cells to improve on their motility and count in a man 
with poor and low sperm quality and stimulating the ovaries of a woman with human 
menopausal gonadotropin or follicle-stimulating drugs, followed with the induction of 
ovulation using human chorionic gonadotrophin. This type of treatment is beneficial 
for women with cervical mucus problems, as it bypasses the cervix with a special 
catheter to deliver specially prepared sperm into the body of the uterus (Strauss & 
Barbieri, 2009). This treatment option is not considered for women with blocked 
fallopian tubes! 
In-vitro fertilization is a minimally invasive procedure that requires 
stimulation of the ovaries with exogenous human menopausal gonadotropin (HMG) 
or follicle-stimulating hormone (FSH), a collection of eggs (ova), fertilization of the 
eggs with viable spermatozoa, and transfer of the generated embryos into the uterus. 
This procedure is the only way to bypass blocked fallopian tubes to treat infertility 
(American College of Obstetricians and Gynaecologists, 2000). While some couples 
can take advantage of these options to conceive, other couples are unable to do so 
because of the cost of treatment, lack of insurance coverage, limited availability of 
ART, complications from treatment, and location (Letoumeau et al., 2012; Seifer, 
Frazier, & Grainger, 2008).  
Help-seeking behavior of women with infertility varies across ethnicity, 
educational level, and geographical location. Even with reduced cost, increased 
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insurance coverage, and availability of treatment, some infertile women still do not 
attempt the procedure, especially Blacks or African Americans, for reasons which are 
unclear (Seifer et al., 2008). Some may delay accessing care because of 
stigmatization, lack of awareness, and cultural beliefs (Bitler & Schmidt, 2006; Seifer 
et al., 2008). 
Drug Treatment Protocol for IVF  
Chandra et al. (2005) and Zegers-Hochschild et al. (2009) established that 
stimulation of ovaries is a crucial component of in-vitro fertilization. This procedure 
requires using gonadotrophic releasing hormones analogs, such as human menopausal 
gonadotropin (HMG), stimulating follicle hormone (FSH), and estradiol (E2) 
inhibitors to stimulate the ovaries. The discoveries of these hormones have made it 
possible for women who could not achieve pregnancy through natural means to 
become pregnant through assisted reproductive techniques by way of in-vitro 
fertilization (Chandra et al., 2005; Zegers-Hochschild et al., 2009).   
Scholars have posited that different regimens could be used to stimulate the 
ovaries for in-vitro fertilization (IVF) using gonadotropin-releasing hormone analogs, 
human menopausal gonadotrophin (HMG), clomiphene citrate (CC), or a combination 
of HMG, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), 
clomiphene citrate or a combination of HMG, FSH, and LH (Ali et al., 2012; ASRM, 
2014; Chandra et al., 2005; Dakhly et al. 2016; Toftager et al., 2016; Zegers-
Hochschild et al., 2009).  
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According to Ludwig et al. (2000), there are two classes of GnRH analogs: 
GnRH agonist and antagonist. These classes are used to classify IVF treatment 
protocols into the following: 
1. Long agonist protocol: This requires the introduction of agonist drugs at the 
mid-luteal phase (Fluker et al., 2001; Ludwig et al., 2000). 
2. Short antagonist protocol: This involves the introduction of antagonist drugs 
on day five or seven of ovarian stimulation or at ovarian follicle size of 14 mm 
together with the gonadotrophin (Ludwig et al., 2000; Olivennes & Frydman, 
1998). 
3. Minimal stimulation protocol: This requires the use of CC in combination with 
FSH and LH for five days starting on day two of a natural cycle (Ferraretti & 
Gianaroli, 2014; Ibrahim, 2014; Keay, 2002; Mohsen & El Din, 2013).  
The purpose of administering gonadotrophins in the IVF cycle is to optimize 
the number of follicles generated for IVF treatment (Templeton & Morris, 2008). 
Gonadotrophin analogs inhibit early luteinizing hormone surge, which results in 
improved oocytes retrieval rate and, therefore, a higher chance for more embryo 
generation and expected pregnancies in IVF treatment (Templeton & Morris, 2008). 
The agonists down-regulates the pituitary gland after administration following initial 
hypersecretion of gonadotrophin, causing desensitization and suppression of the 
gland. On the other hand, antagonists competitively block gonadotrophin receptors 
due to the higher affinity for the receptor sites, thus preventing the sudden surge of 
LH (Vlaisavljevic, Reljic, Lovrec, & Kovacic, 2003). Several studies have 
demonstrated that long agonist protocol favors more egg production when compared 
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with the antagonist protocol (Albano et al., 2000; Fluker et al. 2001; Olivennes & 
Frydman, 1998; Williams, Gibbons, Muasher, & Oehninger, 2002). 
Most women find the long agonist protocol more favorable because of better 
luteal phase development and pregnancy outcome (Vlaisavljevic et al., 2003), which 
is the ultimate aim for stimulating the ovaries of women seeking IVF intervention for 
infertility. However, the long agonist protocol requires more consumption of 
gonadotrophins, which is more costly, and the duration of the treatment cycle is more 
extended (Itskovitz-Eldor, Kol, & Mannaerts, 2000; Templeton & Morris, 2008). 
Short antagonist protocol is less costly because it involves few gonadotrophins 
use, has a shorter treatment duration, and is a good stimulation outcome for women 
who have reduced ovarian activity and are referred to as poor responders. The 
minimal stimulation protocol shares the same advantages as short antagonist protocol 
where fewer gonadotrophins are used, the treatment cycle is very short, and the 
outcome is equally good (Badrawy, Al-Inany, Hussein, Zaki, & Ramzy, 2005; 
Ibrahim, 2014; Mohsen & El-Din, 2013; Zhang, Chang, Sone, & Silber, 2010).  
Risks Associated With In Vitro Fertilization Treatment 
IVF treatment, like any other intervention, is not without risk. The two most 
pronounced associated risks of IVF treatment are maternal-fetal and neonatal risk 
(Armour & Callister, 2005; Dunson et al. 2004; Strong, 2003). The most frequently 
reported associated risks are multiple gestations and ovarian hyperstimulation 
syndrome, which depend significantly on the type of treatment protocol used, age, and 
the number of embryos transferred (Gambone, 2006; Onuh, 2017; Rebar & 
DeCherney, 2004; Schieve et al., 2002; Strong, 2003).  
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According to Gambone (2006), there has been a steady increase in multiple 
gestations due to IVF since 1980, with triplet and quadruplet pregnancies accounting 
for 50% of the IVF gestations and deliveries. The incidence of preterm babies of 33 
weeks is significantly higher with IVF treatment (El-Touchy, Bhattacharya, & 
Akande, 2018). Twenty-two percent of singleton, 14% of twin, and 41% of triplet IVF 
pregnancies end up as preterm deliveries (El-Touchy et al., 2018). There is a potential 
risk of low birth weight, cerebral palsy, hyaline membrane disease, respiratory 
distress, physical disabilities, congenital malformation, and death within the first year 
of life with preterm deliveries (Gambone, 2006; Kurinczuk, Hansen, & Bower, 2004; 
Schieve et al., 2002; Strong, 2003).  
Also, there are associated maternal risks, such as preterm labor, occurring at 
the rate of 15%, 40%, 75%, and 99% for a singleton, twin, triplet, and quadruplet 
gestations, respectively (Strong, 2003). Higher rates of gestational diabetes, pre-
eclampsia, early rupture of membrane, cesarean sections, and high maternal mortality 
were also reported to be associated with IVF treatment (Onuh, 2017; Strong, 2003; 
Wada, 2015). 
Despite these associated risks and consequences, the advent of this technology 
has made several women pregnant. Some couples are reluctant to use IVF for fear of 
cost and low success rate (CDC, 2005). The cost of IVF treatment is a big concern 
because it limits access. Less than 10% of infertile couples participate in IVF 
treatment (Smith et al., 2003). Many factors are contributing to the reported low 
success rate of IVF treatment. These factors could be patient-related, personal issues, 
and the procedure itself. Notwithstanding, successful, favorable clinical pregnancy 
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rates of about 40% and more have been reported for complete IVF treatment cycles 
that end with embryo transfer (Wright, Schieve, Reynolds, & Jeng, 2003). 
Infertility Treatment and Stimulation Influenced by Socioeconomic Status and 
Demographic Characteristics 
Ho et al. (2017) showed that college-educated women presented to fertility 
clinics approximately 8.4 months earlier than those without a college education. Also, 
those reporting an income greater than $100,000 often came to fertility clinics six 
months before those with an income of less than $100,000. The probability of 
achieving pregnancy was significantly higher for those women with higher incomes 
and college educations (Datta et al., 2016). Datta et al. (2016) stated that there is 
evidence of the relationship between socioeconomic status and infertility. Infertility is 
a common issue among women with higher degrees when compared to those with 
lower degrees (Datta et al., 2016). 
The incidence of infertility was greater amongst women in executive 
positions, like senior managers, executive directors, and such, compared with those in 
regular occupations and positions. James et al. (2011) did not find any association 
between infertility and area-related deprivation at interviews amongst women or men. 
Improved pregnancy rates were reported as more IVF treatment cycles were 
performed (James et al., 2011). 
In another study, socioeconomic status was not a confounder or effect 
modifier when the relationship between IVF treatment and perinatal outcomes was 
examined while adjusting for co-variables, such as age, parity, smoking, gestational 
diabetes, maternal diabetes, and pre-eclampsia. However, as the socioeconomic status 
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increased, the prevalence of IVF pregnancies also increased: The corresponding 
percentages were 3.2% and 1.2% for the highest and lowest SES strata, respectively. 
(Räisänen et al., 2013). Moreover, research conducted by Chethana and Shilpa (2016) 
stated that due to economic reasons, 47.37% of males amongst couples with primary 
infertility had not approached the health care facility. 
Furthermore, Datta et al. (2016), in their study, found that infertility is 
associated with demographic characteristics of partners. They found that the statistics 
of infertile married women or cohabiting partners were higher than in non-married 
women. Also, women who are older than 35 years at the first time of cohabiting were 
found with higher infertility when compared with women who are 25 years or 
younger cohabiting for the first time (Datta et al., 2016). 
Dayal et al. (2009), in another study, portrayed that ethnicity did not 
significantly differ with regards to conception, as African Americans were as likely to 
have successful conception and deliver a live baby as Caucasians. However, African 
American women were more likely to come with idiopathic infertility than White 
women. 
Factors Affecting Long Agonist and Short Agonist Protocol in Infertility 
Treatment 
More clinical pregnancy outcomes were reported using a GnRH agonist 
protocol than clomiphene and the GnRH antagonist protocols combined (Schimberni 
al., 2016). The same study by Schimberni et al. (2016) also revealed that the total cost 
of medications for each baby delivered by IVF technology using GnRH agonist was 
lower compared to the antagonist protocol. However, there was no significant 
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difference for the total amount of FSH administered, days of stimulation, the number 
of follicles and eggs collected, and embryos transferred (Schimberni et al., 2016). 
Similar findings were demonstrated by Salat-Baroux et al. (1988). Groups of patients 
with polycystic ovary disease were treated with GnRH analogs to compare long and 
short protocols for the hypothalamus and anterior pituitary gland desensitization. 
Patients were randomly allocated to each group. In the long protocol group (n = 15), 
decapeptide was administered for 30 days for down-regulation and thinning of the 
uterine endometrium, followed by stimulation of the ovaries using pure FSH. In the 
short protocol group (n = 12), buserelin was administered for 15 days, followed by 
stimulation of the ovaries using pure FSH. Six patients in each of the groups had 
clomiphene citrate until the induction of ovulation. The most favorable results were 
recorded from the long protocol. However, significantly lower androgen 
concentrations were observed on the day of oocyte retrieval in the first group than in 
the second group (p = 0.031). Still, the pregnancy rate was comparable in the two 
groups (Salat-Barooux et al., 1988; Shrestha et al., 2015).  
Shrestha et al. (2015) concluded that despite the lengthy and costly procedure, 
GnRH agonist long protocol ensured agreeable outcomes in most women. Also, 
Engemann et al. (2008) found that the use of the GnRH agonist trigger after the 
administration of GnRH antagonist, combined with adequate luteal phase and early 
pregnancy, reduces the risk of oocyte hyperstimulation syndrome in high-risk patients 
undergoing IVF treatment without affecting nidation of the embryo.  
However, Ho et al. (2008) showed that the short GnRH agonist protocol using 
recombinant gonadotrophins is an effective and relatively cheaper choice for IVF 
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treatment. The total cost of recombinant gonadotrophins was significantly lower (p = 
0.025) in the short protocol ($950) compared to the long protocol ($1,580), but there 
were no significant differences in the rates of term pregnancy between the short and 
long protocol. Ou, Xing, Li, Xu, and Zhou (2015) demonstrated that regardless of 
patient’s age, the long protocol was superior to the short protocol regarding the 
number of retrieved oocytes and the implantation and pregnancy rates. 
Barut, Agacayak, Bozkurt, Aksu, and Gul (2016) found a significant 
relationship between socioeconomic status and ovarian reserve parameters, such as 
the level of Mullerian inhibitory substances and antral follicular number. They also 
found a highly significant association (p = 0.021) between socioeconomic status and 
the level of follicle-stimulating hormones. 
Factors Affecting the Help-Seeking Behavior of Women Desiring Fertility 
Treatment 
Lam, Broaddus, and Surkan (2013) showed that knowledge of infertility was 
related to “help-seeking behavior” of infertile women, even after adjusting to socio-
demographic variables. Amongst women with only primary school education, literate 
women’s odds of identifying “getting permission” as a barrier to healthcare were 23% 
less than illiterate women’s odds. For married women, the odds of making decisions 
related to their health were 37% higher in literate than uneducated women. 
Comparing literate to illiterate women in the subsample with no formal schooling, 
odds of reporting “getting permission” as a barrier were 35% lower, odds of having 
decision-making ability were 57% higher, and odds of having sought care for 
experiences of STI-related symptoms were 86% higher (Lam et al., 2013). 
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Complementary Alternative Medical Treatment of Infertility 
Additional alternative medical (CAM) treatment is any non-drug 
interventional approach that is perceived to improve the health or total well-being of 
humans (Olshansky, 2000).CAM involves a wide range of interventions, such as 
bioenergetics, traditional therapies, mind and body conditioning, and spiritual 
principles, given healing to the body. CAM varies in efficacy, safety, cost, and 
outcome (Olshansky, 2000). 
Complementary and alternative medicine has, in recent times, gained 
popularity in infertility treatment. Some women prefer the natural pathway to 
conception than any new intervention. Such women take responsibility to indulge in 
lifestyle modifications and practices that improve their health outcomes to treat 
infertility rather than rely on taking modern medicine and ART to conceive (Coulter 
& Jenkins, 2005). 
Vitamin E, Selenium, and high doses of vitamin C and Zinc are used to 
improve the quality of sperm motility and morphology, and they count as a treatment 
for male-related infertility (Coulter & Jenkins, 2005). Vitamin E promotes the zona 
binding during in vitro fertilization specifically. Anovulatory conditions and 
oligomenorrhea were reported to have been treated with Agnus Castus (Olshansky, 
2000)  
Coulter and Jenkins (2004) showed that acupuncture improved anovulatory 
conditions and uterine and endocrine blood flow, which are very important in female 
fertility. Other studies have also revealed that acupuncture modulates the body’s 
endocrine system to induce or stimulate ovulatory function 35% of times with 
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significant pregnancy outcomes (Beal, 1999; Hanlon, 2004; Olshansky, 2000). Other 
benefits of CAM include the physical and psychological well-being of infertility 
sufferers (Hanlon, 2004). 
A proper and balanced diet is an alternative measure to improve female and 
male fertility (Meletis & Barker, 2004). Food is medicine, and a well-balanced diet 
with fruits helps to enhance several body systems and metabolic activities, including 
the female reproductive system (Ogle & Mazzullo, 2002). Choosing from a broad 
range of foods, as recommended by the American Dietetic Association, using the food 
pyramid for daily consumption is critical to the healthy eating that promotes 
conception (Bruce & Thatcher, 2000). On the other hand, alcohol, caffeine, and 
refined foods with additives half the chance of conception (Hakim et al., 1998). 
Caffeine notably potentiated the effect of alcohol, and women who consumed higher 
than 7 g per month of caffeine were more at risk of infertility associated with 
endometriosis and tubal factors compared to women who consumed the recommended 
3 g per month (Grodstein, Goldman, Ryan, & Cramer, 1993)  
Some studies also considered reflexology as an alternative, complementary 
approach to fertility treatment. Reflexology uses the nerve plexus reflexes at the feet 
and hand nerve endings to control specific organs of the body. Nerves corresponding 
to a particular organ are identified and manually manipulated to bring about healing 
and succor to that organ through rejuvenation and restoration of hormonal balance to 
improve reproductive health (Brown, 1999; Childbirth Index, 2018). 
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Barriers to Infertility Treatment 
IVF has recorded substantial success worldwide (El-Touchy et al., 2018). 
However, huge barriers have prevented a large population of infertile women from 
accessing assisted reproductive technology. The existence of these barriers to 
treatment results in infertility being a chronic condition with attendant emotional 
distress to many couples (Mohammadi & Kaf, 2010; Mosalanejad, Parandavar, & 
Abdollahifard, 2013). This situation is prevalent in low-middle income countries like 
Nigeria (Adegbola, 2013). 
Access to IVF treatment can be very daunting, prohibitive, and almost 
impossible to many infertile women aspiring to conceive in Nigeria, despite the 
stigmatization, social pressure, adverse effects of living without a child, and the 
emotional and psychological morbidity they experience. Sadly, the psychological and 
emotional morbidity associated with childlessness is more in women in Nigeria 
because of widespread beliefs that attribute the cause of infertility to the woman while 
ignoring male-related factors (Daniluk, 2005; Kingly, 2017; Peddie, van Teijlingen, & 
Bhattacharya, 2005). 
Income is a strong predictor of access to quality healthcare (Kate, 2014). The 
financial cost of infertility treatment in Nigeria could be higher than $2,800 per 
complete cycle in a country where 94.2% of the population live below the poverty 
line with a daily earning of less than $2 (Devine, Stillman, & DeCherney, 2014; 
Kingly, 2017). Consequently, most of the women seeking IVF treatment often 
discontinue treatment and resort to traditional and faith healers. These health-seeking 
practices are linked to increased maternal mortality rates in Nigeria (Kingly, 2017). 
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Universal coverage for healthcare as contained in Sustainable Development 
Goals (SDG) is targeted at promoting the health of the people through equal access to 
healthcare and improving the financial burden thereof as a result of ill-health. None of 
the health maintenance organizations in Nigeria pays for infertility treatment, and this 
development leaves infertile couples to pay out their pockets. A considerable number 
of couples who cannot afford such treatments are left to their fate. 
Countries such as Denmark, Belgium, Germany, Canada, Israel, Australia, and 
some US states pay for infertility treatment, thereby providing more access to better 
healthcare (Kingly, 2017). Denmark offers unlimited access to treatment for infertile 
women and men, while in Belgium, infertile women can access treatment for up to six 
treatment cycles (Kingly, 2017; Van Dongen, Verhagen, Dumoulin, Land, & Evers, 
2010).  
Geographical location, long-distance to ART facilities, and lack of adequate 
ART skills amongst physicians are strong barriers to infertility treatment (Gameiro, 
Boivin, & Peronace, 2012; Van Dongen et al., 2010). Some infertile women 
discontinue treatment for fear of daily injection and pain at injection sites. Unwanted 
side effects of IVF medications and the fear of anticipated treatment failure also 
contribute to reduced access to treatment (Wada, 2015). 
Culture and beliefs have a negative impact on access to infertility treatment. In 
Nigeria and other developing African countries, married women are often blamed for 
infertility problems, even when the evidence is contrary (Dyer, Abrahams, Hoffman, 
& van der Spuy, 2002). Married men are considered fit and usually have reasons not 
to be present for medical checks and resort to blaming the women for their infertility 
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problems, which is supported by the prevailing cultural norms. The result of such 
beliefs and cultural practices is delayed infertility (Okoroike, 2009) 
However, studies have shown that educational level affects infertility seeking 
behavior of infertile women (Hammoud et al., 2009; Terava, Gissler, Hemminki, & 
Luoto, 2008), as more educationally developed infertile women are seen to present 
early to infertility clinics than the uneducated women. This is not unconnected to the 
fact that the more educated infertile women are more likely to be aware of the 
importance of seeking early help to address their infertility status. 
Current Trends in Infertility Treatment 
Fertility Preservation 
Recent studies in infertility treatment now focus on fertility preservation 
procedures, which require freezing of eggs and, more recently, freezing of whole 
ovarian tissue. The former technique needs long stimulation of the ovaries with drugs 
to generate eggs, usually 15-30 for freezing. In most cases, less than 2% will be 
successfully frozen and saved for use in the future. Freezing of whole ovarian tissue is 
a new and very promising procedure that is still at the developmental stage. Freezing 
whole ovarian tissue requires micro-surgically separating the thin outer membrane of 
the ovary containing eggs to allow for freezing (Wada, 2015). The harvested and 
frozen tissue, including over approximately 150,000 eggs, can be surgically replaced 
when the woman is ready to become pregnant to offer younger fertility than the 
current age of the woman. This makes natural conception possible. 
Freezing ovarian tissue is targeted at young women in their 30s who are very 
conscious of their biological clock (e.g., career women and women diagnosed with 
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cancer who are on chemotherapy and radiation). Women may wish to preserve their 
fertility until when they are ready to conceive, thus delaying ovarian failure or early 
menopause, which could pose as a challenge for achieving pregnancy naturally, even 
with ART. 
Preimplantation and Genetic Diagnosis 
Pre-genetic diagnosis (PGD) or pre-genetic screening (PGS) is a modern 
value-added technological approach in ART aimed at improving pregnancy outcomes 
(Mastenbroek et al., 2007). The argument about whether IVF babies are healthy or not 
has been and still is a big subject of debate. 
PGD, when combined with IVF, allows couples to give birth to offspring that 
are free from known genetic defects. PGD prevents the babies from carrying recessive 
mutated genes that may manifest in subsequent generations (Mastenbroek et al., 
2007). PGD also provides answers and solutions to miscarriages in healthy and IVF 
pregnancies in both young and mostly older women (Keskintepe et al., 2009) and 
could be used for sex selection in IVF procedures, with 99.9% certainty (Danga, 
2015). The PGD/PGS is used either to eliminate disease carrier genes or for 
aneuploidy screening, where the number of chromosomes is being tested (Danga, 
2015). Prospective and randomized studies have shown that despite the extra cost, 
there is no significant difference in the rate of nidation and pregnancy outcomes 
among older women who did PGD with IVF and infertile women who did only IVF 
procedure (Mastenbroek et al., 2007). 
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Literature Gap 
Infertility treatment has started gaining momentum and attention from 
different quarters in Nigeria, with many fertility treatment centers springing up all 
over the country. However, access to treatment and standard treatment guidelines 
remain a huge issue of concern, as the number of diagnosed and undiagnosed infertile 
women in Nigeria is on the rise. Education, ethnicity, age, religion, socioeconomic 
status, and cost are determinant factors affecting access to treatment (Bitler & 
Schmidt, 2006; Seifer et al., 2008). 
In some instances, insurance coverage was provided to pay for treatment, and 
the cost was significantly reduced. Yet, the more educated White women seem to 
make the most of the opportunity by presenting in fertility clinics for treatment while 
Black American women were reluctant to access treatment for fear of stigmatization, 
belief, and lack of awareness (Bitler & Schmidt, 2006; Seifer et al., 2008).  
No study yet in Nigeria has critically examined the available treatment 
protocols. Instead, individual protocols were reported. Long agonist protocols are 
more time consuming, require more drugs, and the rate of treatment cancellation was 
reported to be high when compared to the short antagonist protocol, which required 
fewer drugs, is less expensive, required lesser time to complete treatment cycle, and is 
suitable for poor responders, with minimal cancellation rate (Itskovitz-Eldor et al., 
2000; Mohsen & El-Din, 2013; Templeton & Morris, 2008; Zhang et al., 2010;). The 
treatment outcomes of these protocols, socio-economic status, and other determinant 
factors were not studied in the reviewed literature during the period of this study.  
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Therefore, there was a need to resolve the gaps identified in the literature. The 
focus of this study has been on the Nigerian situation by studying existing data from 
the 10 fertility centers across the six geopolitical zones. The study critically assessed 
factors that impact treatment protocol and outcome and to determine which treatment 
protocol was best for infertile women in Nigeria. 
Summary of Literature Review 
The purpose of this study was to assess the factors that affect treatment 
outcomes in women with infertility issues and treatment protocols that are currently 
being used in IVF procedures. The reviewed literature highlighted the importance of 
childbirth in every marriage, especially in Africa, where childbirth is considered as 
necessary in marriage, without which the marriage is considered as not consummated 
and remains at risk of divorce (Okoroike, 2009). The literature review identified 
uterine and endocrine factors, infections, and surgeries, amongst other issues as 
plausible causes of infertility issues in couples.  
The advent of IVF technologies since the 80s has ameliorated the biological 
gap in couples finding it difficult to reproduce (Cristia, 2008; Lundborg et al., 2017). 
Despite the availability of this technology, determinant factors such as socioeconomic 
status, social-demographics, culture, and belief have been reported to influence the 
success of this technology. Still, the know-how has not been adequately studied. 
Furthermore, the IVF treatment protocols and other non-drug approaches to treatment 
have not been critically assessed to identify which is more favorable for countries like 
Nigeria, where access to this technology is challenging because of cost and other 
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behavioral determinant factors. These gaps in knowledge are the fundamental reasons 
why this study was embarked upon. 
The current trends in the treatment of infertility, such as pre-implantation 
genetic diagnosis, and fertility preservation, were also presented in this chapter. PGD 
helps to minimize the chances of giving birth to genetically deformed babies by 
infertile women through IVF, and the fertility preservation technique provides for 
women to suspend childbirth till a later date. This is useful for career women and 
women undergoing chemotherapy and radiotherapy due to cancer. The detailed 
methodological approach used to provide answers to the research questions raised in 
Chapter 1 is explained in the next chapter.  
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Chapter 3: Research Method 
This study was a retrospective, cross-sectional, quantitative, and 
nonexperimental study that assessed the relationship between types of fertility 
treatment protocol and treatment outcome. The secondary data of ART were collected 
from 10 fertility centers in five states covering the entire six geopolitical zones of 
Nigeria from January 2015 through December 31, 2017. This observational study 
required a retrospective collection of data from an existing database of previously 
completed IVF treatments. Although cross-sectional studies have some limitations, 
such as lack of representativeness, it was suitable for this study because fertility 
treatment is not very popular in Africa. This study covered 10 accredited fertility 
centers in Nigeria. 
Research Design and Rationale 
This study was quantitatively designed to capture data available in Nigeria on 
fertility treatment between January 2015 through December 31, 2017, in 10 fertility 
treatment centers of five states covering the entire six geopolitical zones of Nigeria. 
The observational, cross-sectional, retrospective and quantitative study design 
had many advantages. It was used to provide the odds ratio, relative risk, and absolute 
risk from a prevalence study. Exposures with multiple outcomes could be 
conveniently studied, and this type of design avoids a loss to participant follow-up 
issues, which made it suitable for this study (see Creswell, 2014). Other strengths of 
this research design included the minimal influence of the investigator or researcher 
on results and that the findings or research outcomes can be generalized when based 
on large sample sizes (see Creswell, 2014). Hence, this design was appropriate and 
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efficient to answer my research questions. Also, the plan was relatively cheap 
compared to experimental design. 
Study Area 
This study was carried out in Nigeria, located in sub-Saharan Africa. Other 
West African countries border it: Niger, Chad, Cameroon, and Benin. The south coast 
of Nigeria hinges on the Gulf of Guinea. It is made up of 36 states and a Federal 
Capital Territory (see Figure 2). 
Nigeria was founded in the year 1914 during British colonial rule. It became a 
sovereign and independent nation on October 1, 1960. It is popularly referred to as the 
“Giant of Africa” because of its large population and the size of the economy. It is a 
highly diversified country, and the estimated population as of the 2006 Census was 
185,989,640. Nigeria has over 250 ethnic groups and more than 350 languages 
(National Population Commission, 2006). The official language in Nigeria is English. 
Christianity and Islam are the two dominant religious groups in Nigeria.  
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Figure 2. Map showing the 36 states and the federal capital territory in Nigeria. 
Study Population 
The candidate population for this study was comprised of infertile women who 
have been enrolled in the enlisted health facilities and have had IVF complete 
treatment between January 1, 2015, and December 31, 2017. The selected health 
facilities for this study were composed of all the registered hospitals and clinics with 
the Nigeria Ministry of Health and Association for Fertility and Reproductive Health, 
who are licensed to carry out this specialist cadre of treatment, ART (see Table 1).  
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Table 1 
List of Health Facilities 
Region Hospital or clinic 
Abuja  Nisa Fertility and Genetic Center 
 Fertil Aid Clinic 
 Deda Hospital 
 Charitos Bo Hospital 
 
Lagos  Garki Hospital 
 
 
Port-Harcourt  Nisa at Prime Hospital 
 El-Rapha 
 
Jos  Kauna Hospital 
 Fertile Ground Hospital 
 
 
Enugu  Alps Hospital 
 
These facilities were selected across Nigeria because they were first- and 
second-generation fertility treatment centers that are registered by law and are 
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licensed by the relevant authorities and association in Nigeria to carry out IVF 
treatment. These facilities provide high-quality care with a large clientele base, have 
official medical records, have standard ICT units, and are easy to access. 
Sample Size 
In research, studying the entire population is impossible, especially when the 
population under investigation is significant, hence the need for a representative 
sample of the population under study. Several factors determine the calculation of the 
sample size, such as the nature of variables that could be categorical or continuous, 
the type of test statistics, level of significance, marginal error, and the 
interrelationship between variables. Fisher’s formula was used to compute the 
minimum sample size for this study (as cited in Abuh, 2013): 
n = z
2
pq/𝛿2 
Where 
n = sample size 
z = 1.96 
p = proportion or prevalence of the disease or condition in the 
population under study.  
Q = level of precision (1−p) 
𝛿2 = the allowed margin of error or the degree of accuracy. 
The prevalence studies showed that the proportion of women who are infertile 
in Nigeria ranges from 30 to 50%. Hence p is considered at 50% = 0.5 
Therefore, values for the parameters are 
P = 0.5 
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z
2 
= (1.96)
2 
= 3.8416 
q = 1-p = 1-0.5 = 0.5 
𝛿2 = (0.05)2 = 0.0025 
By substituting these values in the formula 
N = 3.8416 x (0.5 x 0.5) / 0.0025 
  = (3.8416 x 0.25) / 0.0025 
  = 0.9604 / 0.0025 
  = 384.16 
n = 385 (approximate value) 
A minimum of 385 treatment records of infertile women were computed as the 
sample size for the example above, but 605 records were used in this study. 
Sampling Method 
Convenience or a purposive nonprobability sampling method was employed in 
this study. All available medical charts of women accessing infertility treatment in the 
selected hospitals formed the sampling frame from which the sample size was 
selected. The medical charts, with complete variables of interest, formed the study’s 
sample size.  
Inclusion Criteria 
1. The women had primary or secondary infertility as diagnosed by a physician. 
2. The age of the participating women was 20 to 50 years. 
3. The women had completed at least one fertility treatment cycle between 
January 1, 2015 and December 31, 2017. 
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Exclusion Criteria 
1. Patients who had timed intercourse, intrauterine insemination, and minimal 
stimulation. 
2. All frozen embryo transfers and surrogacy. 
Gaining Access to the Data 
Data were accessed following the presentation of the study proposal and 
Walden Institutional Review Board approval number 0815190326544 to the hospital 
management, and verbal approval was given to access the data after signing the 
agreement form. 
Operationalizing the Variables 
The quantitative independent variables of this study were age, ethnicity, 
education, religion, tribe, PCOS, endometriosis, a drug used for down-regulation, 
duration of down-regulation, a drug used for stimulation, and duration of stimulation, 
while the number of follicles/oocytes retrieved was the dependent variable. 
Data Collection 
Following the approval of the Walden University Institutional Review Board 
and the management of the hospitals, data were collected on Microsoft Excel 2010 
spreadsheets from the medical records of the selected 10 fertility centers. Ten well-
trained research assistants were used for this purpose. The collected data were 
harmonized, merged, and cleaned using Epidata software and exported to the SPSS 
Version 25 statistical software for analysis. 
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Data Analysis Plan 
Data were analyzed using SPSS version 25. Descriptive and inferential 
statistics were performed on the data. Univariate test statistics were used to describe 
the characteristics of patients, and the results were presented in the forms of tables, 
figures, and charts. Non-parametric statistics, the Wilcoxon rank-sum, Kruskal-
Wallis, and Pearson’s correlation tests were used to test the hypotheses. Regression 
analysis was used to determine which variables were statistically significant 
predictors of the treatment outcomes. The decision rule was considered at p < .05 
(Kestin, 2015). 
Validity 
Validity is to ensure that the result of the study is reliable and trustworthy, and 
measures up to what it was originally designed to achieve (Golafshani, 2003). 
However, the impacts of threat were minimized by capturing all the variables of 
interest and the large sample size for generalization in this study.  
Ethical Consideration 
Ethical consideration is an essential aspect of every research, especially when 
the research involves human subjects. Hence, ethical principles of doing no harm, 
respect, beneficence, confidentiality, and justice for human subjects guided this study, 
as laid out in the Belmont Report (U.S. Department of Health & Human Services, 
Office for Human Research Protections (2016). All approvals were obtained before 
data were collected. 
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Post Data Analysis Plan 
The collected data have been pass-word protected and will be saved for a 
minimum period of 5 years.  
Summary 
The study is a retrospective and quantitative design. Secondary data from 10 
fertility clinics and hospitals across Nigeria were used to answer the research 
questions. Data were collected following approval from Walden Institutional Review 
Board and hospital management. The collated data were cleaned and exported to 
SPSS software version 25 and analyzed. Results were presented in tables and graphs. 
This marks the end of Chapter 3, and the details of the results are presented in Chapter 
4. 
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Chapter 4: Results 
This cross-sectional and retrospective study was conducted using secondary 
data of women who had completed fertility treatment from 10 selected hospitals 
across Nigeria between January 1, 2015, and December 31, 2017, to establish the 
relationship between long and short treatment protocol and to determine which 
protocol is most favorable for Nigeria. Patient characteristics, including age, medical 
conditions (PCOS and endometriosis), SES, education, ethnicity, the drug used for 
down-regulation, duration of down-regulation, the drug used for stimulation, and 
duration of stimulation were also examined to determine the impact on treatment 
outcome. As at the time of this report, no researcher had conducted this study in 
Nigeria.  
The research questions and hypotheses that guided this study were as follows: 
RQ1: What is the relationship between types of fertility treatment protocol and 
treatment outcome? 
H01: There is no significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
H11: There is a significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
RQ2: Do patient characteristics (age, education, SES, medical condition, 
previous IVF, ethnicity) influence the outcome of fertility treatment protocol? 
H02: Patient characteristics have no significant influence on the outcome of 
the fertility treatment protocol. 
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H12: Patient characteristics have a significant influence on the outcome of the 
fertility treatment protocol. 
Summary Description of the Variables 
Table 2 
Descriptive Statistics of the Variables 
Variables 
Overall 
(N = 605) 
Hospital (%)  
 ALPS 60 ( 9.9) 
 Charitos 61 (10.1) 
 Deda 60 ( 9.9) 
 Alpha 60 ( 9.9) 
 Fertilaid 60 ( 9.9) 
 Fertile Ground 59 ( 9.8) 
 Garki 60 ( 9.9) 
 Kauna 60 ( 9.9) 
 Nisa At Prime 60 ( 9.9) 
 Nisa Premier 65 (10.7) 
 
Tribe (%)  
 Hausa 173 (28.6) 
 Igbo 184 (30.4) 
 Yoruba 93 (15.4) 
 Others 155 (25.6) 
 
Education (%)  
 Primary 23 ( 3.8) 
 Secondary 168 (27.8) 
 Tertiary 414 (68.4) 
 
Age (mean (SD)) 35.5 (5.2) 
 
Age Group (%)  
 20-24 8 ( 1.3) 
 25-29 62 (10.2) 
 30-34 183 (30.2) 
 35-39 234 (38.7) 
 40-44 91 (15.0) 
 45-49 24 ( 4.0) 
 50-54 3 ( 0.5) 
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Variables 
Overall 
(N = 605) 
 
Religion = Christianity/Islam (%) 429/176 (70.9/29.1) 
 
 
 
(table continues) 
 
Socioeconomic status (%)  
 Low 70 (11.6) 
 Medium 274 (45.3) 
 High 261 (43.1) 
 
Polycystic ovary syndrome = No/Yes (%) 366/239 (60.5/39.5) 
 
Endometriosis = No/Yes (%) 368/237 (60.8/39.2) 
 
Treatment protocol = Long/Short (%) 224/381 (37.0/63.0 
) 
The drug used for downregulation (%)  
 Buserelin 352 (58.2) 
 Cetrotide 67 (11.1) 
 Zoladex 186 (30.7) 
 
GnRH drug = GnRH agonist/GnRH antagonist (%) 538/67 (88.9/11.1) 
 
Duration of downregulation in weeks (%)  
 1 34 ( 5.6) 
 2 326 (53.9) 
 3 245 (40.5) 
 
The drug used for stimulation (%)  
 HMG 457 (75.5) 
 FSH 139 (23.0) 
 FSH & HMG 9 ( 1.5) 
 
Duration of stimulation in days (median [IQR]) 11.0 [9.0, 12.0] 
 
Number of oocytes (median [IQR]) 5.0 [2.0, 10.0] 
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A total number of 605 women’s fertility treatment data from 10 accredited 
fertility hospitals across Nigeria were assessed. The mean age was 35.5, and 38% of 
the women were within the age group 35 to 39. The women were predominantly 
Christian, 70.9%. The Igbo women accounted for 38.4%, Hausa 28.6%, Yoruba 
15.4%, and other 25.6% of the study sample. Most of the women had a higher degree, 
68.4%, and 45.3% of the women were medium-income earners. 
PCOS and endometriosis accounted for 39.5% and 39.2%, respectively. Of the 
participants, 63% of the women had short protocol treatment, and 37% had long 
protocol treatment. The median duration of stimulation and the number of oocytes 
were IQR 11.0(9.0, 12.0) and IQR 5(2.0, 10.0). 
Research Question 1 
What is the relationship between types of fertility treatment protocol and 
treatment outcome? 
H01: There is no significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
H11: There is a significant difference in the relationship between fertility 
treatment protocol and treatment outcome. 
• The independent variable was the type of fertility treatment protocol 
measured as a nominal variable (values = long, short). 
• The dependent variable was treatment outcome measured as the number of 
eggs (oocytes) - range: 1, 38. 
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Figure 3. Histogram and density plot of the outcome variable (number of oocytes). 
 
Both the histogram and density plot of the outcome variable presented in 
Figure 3 show that it right-skewed and is not a normal distribution. Furthermore, I 
tested the hypothesis for normality using the Shapiro-Wilk Normality test, which 
showed that the distribution was not normally distributed. 
Due to the nonnormal distribution of the outcome variable, the hypothesis that 
reflected no significant difference in the relationship between fertility treatment 
protocol and treatment outcome was tested using the Wilcoxon rank-sum test. For 
RQ1, the median number of oocytes of the long protocol group and the short protocol 
group were 8 and 4, respectively. The Wilcoxon rank-sum test showed that there is a 
significant effect of the protocol group (W = 54503, p < .001) on the number of 
oocytes (see Figure 4). 
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Figure 4. Boxplot of the number of oocytes by the treatment protocol. 
 
The Wilcoxon rank-sum test analysis in Figure 4 showed that there is a statistically 
significant difference between the numbers of oocytes in the long (median 8) and 
short (median 4) treatment protocols.  
Research Question 2 
Do patient characteristics (age, education, SES, medical condition, ethnicity) 
influence the outcome of fertility treatment protocol? 
H02: Patient characteristics have no significant influence on the outcome of 
the fertility treatment protocol. 
H12: Patient characteristics have a significant influence on the outcome of the 
fertility treatment protocol. 
The independent variables were 
1. Sociodemographic characteristics: 
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• Age measured both as a continuous variable (age) and as a nominal 
variable (age group) 
• Education measured as an ordinal variable (values = primary, 
secondary, tertiary) 
• SES measured as an ordinal variable (values = low, medium, high) 
• Tribe measured as a nominal variable (values = Hausa, Igbo, Yoruba, 
Other) 
• Religion measured as a nominal variable (values = Christianity, Islam) 
2. Medical condition: 
• PCOS (values = yes, no) 
• Endometriosis (values = yes, no) 
3. Treatment-related factors: 
• The drug used during down-regulation (Buserelin, Cetrotide, Zoladex) 
• Type GnRH drug used (agonist vs. antagonist) 
• Duration of down-regulation in weeks 
• The drug used for stimulation (FSH, HMG, FSH & HMG) 
• Duration of stimulation in days 
4. Hospital (This was added to account for a range of effects like the skill of 
provider, etc.) 
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The dependent variable was the number of oocytes. 
Age.  
 
Figure 5. Scatter plot of age versus the number of oocytes. 
 
There is a weak to moderate but statistically significant correlation between 
age and number of oocytes, r = −0.276 (95% CI −0.348, −0.200), p < .001. We could 
also look at how the age groups compare (Figure 6). 
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Figure 6. Boxplot of the number of oocytes by age groups. 
 
The Kruskal-Wallis χ2(6) = 33.4796, p < .001 indicates a statistically 
significant relationship between the Age Group and the Number of oocytes. 
Education. 
 
Figure 7. Boxplot of the number of oocytes by education level. 
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The Kruskal-Wallis, χ2(2) = 7.2751, p = .026, indicates a statistically significant 
relationship between Education and the Number of oocytes. 
Socioeconomic status. 
 
Figure 8. Boxplot of the number of oocytes by socioeconomic status. 
 
The Kruskal-Wallis, χ2(2) = 15.1107, p < .001, indicates a statistically significant 
relationship between Socioeconomic status and the number of oocytes. 
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Tribe. 
 
Figure 9. Boxplot of the number of oocytes by the tribe. 
 
The Kruskal-Wallis, χ2(3) = 13.1976, p < .001, indicates a statistically significant 
relationship between Tribe and the Number of oocytes. 
Religion. 
 
Figure 10. Boxplot of the number of oocytes by religious affiliation. 
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The Kruskal-Wallis, χ2(1) = 5.7181, p = .017, indicates a statistically significant 
relationship between Religion and the outcome of the Number of oocytes. 
Polycystic ovary syndrome. 
 
Figure 11. Boxplot of the number of oocytes by PCOS status. 
 
The Wilcoxon rank-sum, W = 56402, p < .001, indicates a statistically significant 
relationship between Polycystic ovary syndrome status and the outcome of the 
Number of oocytes. 
Endometriosis. 
 
Figure 12. Boxplot of the number of oocytes by endometriosis status. 
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The Wilcoxon rank-sum, W = 52407, p < .001, indicates a statistically significant 
relationship between Endometriosis status and the outcome of the Number of oocytes. 
The drug used for down-regulation. 
 
Figure 13. Boxplot of the number of oocytes by drugs used for down-regulation. 
 
The Kruskal-Wallis, χ2(2) = 76.1251, p < .001, indicates a statistically significant 
relationship between Drugs used for down-regulation and the outcome of the Number 
of oocytes. 
Duration of downregulation in weeks. 
 
Figure 14. Boxplot of the number of oocytes by the duration of downregulation. 
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The Kruskal-Wallis, χ2(2) = 27.3558, p < .001, indicates a statistically significant 
relationship between the Duration of down-regulation in weeks and the outcome of 
the Number of oocytes. 
The drug used for stimulation. 
 
Figure 15. Boxplot of the number of oocytes by the drug used for stimulation. 
 
The Kruskal-Wallis, χ2(2) = 15.2588, p < .001, indicates a statistically significant 
relationship between Drugs used for stimulation and the outcome of the Number of 
oocytes. 
The dose of the drug used for stimulation. 
 
Figure 16. Scatter plot of dose versus the number of oocytes. 
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As shown in the scatterplot in Figure 16, the Pearson’s r = −.152 (95% CI −.229, 
−.073), p < .001 indicates a weak, but statistically significant relationship between the 
Dose (IU) and Number of oocytes. 
Duration of stimulation. 
 
Figure 17. Scatterplot of the duration of stimulation versus the number of oocytes. 
 
The Duration of stimulation in days has a weaker correlation with the Number of 
oocytes, r = −.080 (−.001, −.159), p = .048. 
The relationships between these variables and the number of oocytes are 
summarized in Table 3. 
Table 3 
Summary of Bivariate Relationships Between Variables and the Number of Oocytes 
Variable Test statistics p-value 
Age r = −.276 < .001 
Age Group Kruskal-Wallis χ2(6) = 33.4796 < .001 
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Education Kruskal-Wallis χ2(2) = 7.2751 .026 
Socioeconomic status Kruskal-Wallis χ2(2) = 15.1107 < .001 
Tribe Kruskal-Wallis χ2(3) = 13.1976 .004 
Religion Kruskal-Wallis χ2(1) = 5.7181 .017 
Polycystic ovary syndrome Wilcoxon W = 56402 < .001 
Endometriosis Wilcoxon W = 52407 < .001 
Drug used for down regulation Kruskal-Wallis χ2(2) = 76.1251 < .001 
Duration of down regulation in weeks Kruskal-Wallis χ2(2) = 27.3558 < .001 
Drug used for stimulation Kruskal-Wallis χ2(2) = 15.2588 < .001 
Dose of drug used for stimulation r = −.152 < .001 
Duration of stimulation r = −.080 .048 
The results of the relationships between the variables and the number of 
oocytes are presented in Table 3. The p-values < 0.5 show a significant relationship, 
while p-values >0.5 show no significant relationship. 
Checking for Confounding 
A confounder is related to both the dependent and independent variables but is 
not an intermediate variable in the causal pathway. The bivariate analyses below show 
the relationships between the study subjects’ sociodemographic, treatment-related 
characteristics, and the outcome variable. The relationships between these variables 
and the Treatment protocol group are shown in Figure 18. 
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Age. 
 
Figure 18. Boxplot of age by treatment protocol group. 
 
The median age for the women who had long and short protocols do not differ 
significantly (W = 39.374, p = 0.112).  
Age group. 
 
Figure 19. Boxplot of age groups by treatment protocol group. 
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The Kruskal-Wallis, χ2(6) = 15.9909, p < 0.014, indicates a statistically significant 
relationship between the Age group and Treatment protocol group. 
Education. 
 
Figure 20. Boxplot of education by treatment protocol group. 
 
The Kruskal-Wallis, χ2(2) = 9.1564, p = 0.010, indicates a statistically significant 
relationship between Education and Treatment protocol groups 
Socioeconomic status. 
 
Figure 21. Boxplot of socioeconomic status by treatment protocol group. 
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The Kruskal-Wallis, χ2(2) = 10.5638, p = 0.005, indicates a statistically significant 
relationship between Socioeconomic status and Treatment protocol group. 
Tribe. 
 
Figure 22. Boxplot of the tribe by treatment protocol group. 
 
The Kruskal-Wallis, χ2(3) = 1.7247, p = 0.631, indicates that there is no statistically 
significant relationship between Tribe and Treatment protocol. 
Religion. 
 
Figure 23. Boxplot of religion by treatment protocol group. 
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The Kruskal-Wallis, χ2(1) = 0.7474, p = 0.387, indicates that there is no statistically 
significant relationship between Religion and Treatment protocol group. 
Polycystic ovary syndrome. 
 
Figure 24. Boxplot of PCOS status by treatment protocol group. 
 
The Kruskal-Wallis, χ2(1)= 3.5962, p = 0.058, indicates that there is no statistically 
significant relationship between Polycystic ovary syndrome status and Treatment 
groups. 
Endometriosis. 
 
Figure 25. Boxplot of endometriosis by treatment protocol group. 
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The Kruskal-Wallis, χ2(1) = 13.4327, p = 0.001, indicates a statistically significant 
relationship between the Endometriosis status and Treatment protocol group. 
The drug used for down-regulation. 
 
Figure 26. Boxplot of drug used for downregulation by treatment protocol group. 
 
The Kruskal-Wallis χ2(2) = 60.6749, p < .001 indicates a statistically significant 
relationship between Drugs used for down-regulation and Treatment protocol group. 
Duration of down-regulation. 
 
Figure 27. Bar plot of duration of down-regulation by treatment protocol group. 
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The Kruskal-Wallis, χ2 (2) = 82.9599, p < .001, indicates a statistically significant 
relationship between the Duration of down-regulation in weeks and Treatment 
protocol group. 
The drug used for stimulation. 
 
Figure 28. Bar plot of drugs used for stimulation by treatment group. 
 
The Kruskal-Wallis χ2(2) = 25.2773, p < .001 indicates a statistically significant 
relationship between Drugs used for stimulation and the outcome of the treatment 
protocol group. 
The dose of the drug used for stimulation. 
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Figure 29. Boxplot of the dose of the drug used for stimulation by treatment protocol 
group. 
 
The Wilcox on the rank-sum test, W = 15.2588, p = 0.102, indicates that there is no 
statistically significant relationship between Drugs used for stimulation and Treatment 
protocol group. 
Duration of stimulation. 
 
Figure 30. Boxplot of the duration of stimulation by treatment protocol group. 
 
The Wilcoxon rank-sum test, W = 56152, p < 0.001, indicates that there is a 
statistically significant relationship between the duration of stimulation in days and 
Treatment protocol group. 
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Table 4 
Differences Between Treatment Protocol Groups 
  
Long 
(N = 224) 
Short 
(N = 381) p 
    
Hospital (%)   <0.001 
 ALPS 33 (14.7) 27 ( 7.1)  
 Charitos 42 (18.8) 19 ( 5.0)  
 Deda 49 (21.9) 11 ( 2.9)  
 Elrapha 19 ( 8.5) 41 (10.8)  
 Fertilaid 41 (18.3) 19 ( 5.0)  
 Fertile Ground 2 ( 0.9) 57 (15.0)  
 Garki 2 ( 0.9) 58 (15.2)  
 Kauna 9 ( 4.0) 51 (13.4)  
 Nisa At Prime 15 ( 6.7) 45 (11.8)  
 Nisa Premier 12 ( 5.4) 53 (13.9) 
 
 
Tribe (%)   0.631 
 Hausa 65 (29.0) 108 (28.3)  
 Igbo 74 (33.0) 110 (28.9)  
 Yoruba 33 (14.7) 60 (15.7)  
 Others 52 (23.2) 103 (27.0) 
 
 
Education (%)   0.010 
 Primary 2 ( 0.9) 21 ( 5.5)  
 Secondary 59 (26.3) 109 (28.6)  
 Tertiary 163 (72.8) 251 (65.9) 
 
 
Age (mean (SD)) 35.2 (4.9) 35.6 (5.4) 0.408 
 
Age Group (%)   0.014 
 20-24 1 ( 0.4) 7 ( 1.8)  
 25-29 22 ( 9.8) 40 (10.5)  
 30-34 87 (38.8) 96 (25.2)  
 35-39 73 (32.6) 161 (42.3)  
 40-44 30 (13.4) 61 (16.0)  
 45-49 9 ( 4.0) 15 ( 3.9)  
 50-54 2 ( 0.9) 1 ( 0.3) 
 
 
Religion = Christianity/Islam (%) 164/60 
(73.2/26.8) 
265/116 
(69.6/30.4) 
0.387 
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Long 
(N = 224) 
Short 
(N = 381) p 
 
Table 4 continued 
Socioeconomic status (%)   0.005 
 Low 38 (17.0) 32 ( 8.4)  
 Medium 99 (44.2) 175 (45.9)  
 High 87 (38.8) 174 (45.7) 
 
 
Polycystic ovary syndrome = No/Yes 
(%) 
124/100 
(55.4/44.6) 
242/139 
(63.5/36.5) 
 
0.058 
Endometriosis = No/Yes (%) 158/66 
(70.5/29.5) 
210/171 
(55.1/44.9) 
<0.001 
The drug used for down-regulation 
(%) 
  <0.001 
 Buserellin 125 (55.8) 227 (59.6)  
 Cetrotide 0 ( 0.0) 67 (17.6)  
 Zoladex 99 (44.2) 87 (22.8) 
 
 
GnRH drug = GnRH agonist/GnRH 
antagonist (%) 
224/0 
(100.0/0.0) 
314/67 
(82.4/17.6) 
 
<0.001 
Duration of downregulation in weeks 
(%) 
  <0.001 
 1 0 ( 0.0) 34 ( 8.9)  
 2 83 (37.1) 243 (63.8)  
 3 141 (62.9) 104 (27.3) 
 
 
The drug used for stimulation (%)   <0.001 
 HMG 194 (86.6) 263 (69.0)  
 FSH 30 (13.4) 109 (28.6)  
 FSH & HMG 0 ( 0.0) 9 ( 2.4) 
 
 
Duration of stimulation in days 
(median [IQR]) 
12.0 [10.0, 12.0] 10.0 [9.0, 12.0] <0.001 
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The differences between treatment protocol groups were presented in Table 4. 
The variables with p-values of < 0.05 show that there is a significant difference in 
their relationships, and a p-value of > 0.05 indicates that there is no statistically 
significant difference in their relationships. Those with significant relationships as 
shown in Table 4 may be due to confounding. 
Regression Models 
The relationships between the independent variables and the outcome variable 
can be explored further using regression analyses. Also, the two treatment groups are 
dissimilar about some of the variables, as seen in Figure 31, and so these will need to 
be controlled when using regression analyses. The variables with p ≤ .25 were 
included in the initial regression model. The most parsimonious models were found 
using backward stepwise regression.  
 
Figure 31. Histogram and density plot of the outcome variable (number of oocytes). 
81 
 
 
It is apparent from the density plot that the number of oocytes is right-skewed 
and not normally distributed. This is a deviation from one of the assumptions of linear 
regression models, which requires the dependent variable to be normally distributed. 
Since the outcome variable is not normally distributed, the following approaches were 
explored: (a) linear regression modeling with the log-transformed outcome and 
(b) generalized linear modeling with a Gamma distribution.  
Log Transformation of the Outcome Variable 
We can log-transform the outcome variable as the arithmetic mean: 
 
 
∑   
 
   
 
While the geometric mean is: √∏   
 
   
   
 
 
∑             
So the linear model with the log-transformed outcome is a multiplicative 
geometric mean model, which is modeling the following: 
                                 
Thus 
    
                     
Which is equivalent to: 
    
                        
Note that            
 
 
∑             (i.e., the geometric mean). 
This model is interpretable in terms of the change in the geometric mean. Thus, this 
model assumes multiplicative effects on the primary outcome by the predictors. 
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Table 5 
Model 1 
  β SE t value P 
Intercept 2.369 0.0707 33.52 < .001 
Endometriosis -0.234 0.0735 -3.182 .002 
Short Protocol -0.672 0.0787 -8.582 < .001 
Cetrotide 0.0538 0.1191 0.4512 .652 
Zoladex -0.888 0.0802 -11.08 < .001 
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Table 6 
Model 2 
  Β SE t value P 
Intercept 1.581 0.1364 11.6 < .001 
Endometriosis -0.1099 0.06557 -1.676 0.094 
Short Protocol -0.3529 0.08355 -4.224 < .001 
Cetrotide 0.2732 0.1075 2.541 .011 
Zoladex -0.3237 0.08841 -3.661 < .001 
ALPS -0.03496 0.1409 -0.2481 .804 
Charitos 1.412 0.1556 9.075 < .001 
Deda 0.05215 0.1469 0.3549 .<.001 
Elrapha 0.02513 0.1363 0.1844 .854 
Fertilaid 1.233 0.1561 7.897 < . 001 
Fertile Ground 0.5081 0.1429 3.557 < .001 
Garki 0.3188 0.1405 2.269 < .024 
Kauna -0.06684 0.1358 -0.4921 < .005 
Nisa  -0.02962 0.1434 -0.2066 < .001 
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Model Diagnostics 
There are some assumptions of linear regression; these assumptions are: 
• Homogeneity of variance (homoscedasticity): The error variance should be 
constant. 
• Linearity: The relationships between the predictors and the outcome 
variable should be linear. 
• Independence: The errors associated with one observation are not 
correlated with the errors of any other observation. 
• Normality: The errors should be normally distributed. Technically, 
normality is necessary only for hypothesis tests to be valid. 
• Model specification: The model should be appropriately specified 
(including all relevant variables and excluding irrelevant variables). 
Other issues of concern are: 
• Influence: individual observations that exert undue influence on the 
coefficients 
• Collinearity: predictors that are highly collinear (i.e., linearly related, can 
cause problems in estimating the regression coefficients). 
These assumptions were examined using diagnostic plots (see Figure 32). 
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Figure 32. Diagnostic plots. 
 
Model Interpretation 
There are essential ways commonly used to assess the performance of the 
regression model. These ways are the root mean squared error (RMSE), which 
measures the model prediction error. The RMSE is the average difference between the 
observed values of the outcome and the predicted values. The lower the RMSE, the 
better the model. The    is the squared correlation between the observed outcome 
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values and the predicted values. The higher the   , the better the model. The F 
statistic provides the overall significance of the model. 
From Figure 32, we see that the better model is: 
                      
                                                   
                                          
                                                  
                             
Which is: 
                      
                                               
                                               
                                                  
                                             
                     
Comparing both models shows much of the variance in the data can be 
explained by the Hospital variable; the adjusted         . The second model, 
which incorporates the Hospital, explains 42.2% of the variance in the data compared 
to the first model, which only explains 23.9%. Therefore, more of the effect on the 
treatment outcome could be due to factors related to Hospital and not Treatment 
protocol or patient-related characteristics. 
Recall then that the outcome variable is the log-transformed number of 
oocytes. Therefore, to interpret the coefficients in the model equation, subtract one 
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from this number and multiply by 100 to give the percent increase (or decrease) in the 
dependent variable for every one-unit increase in the independent variable. For 
example, the coefficient (β) for Short Treatment Protocol is −0.353, then 
(       –  )              that is, a 29.7% decrease in the Number of oocytes 
compared to the Long Treatment Protocol 
Summary 
In Chapter 4, descriptive and inferential test statistics were performed to 
examine the relationship, if any, on the long and short IVF treatment protocol and 
patient characteristics on the number of oocytes. Test for normality was conducted on 
the data to see the distribution curve, which showed right skewness and non-
parametric test statistics. Wilcoxon rank-sum test, Kruskal-Wallis, and Pearson 
correlation test statistics were performed to establish the relationship between the 
treatment protocols and the influence of patient characteristics on the number of 
oocytes. The relationships between independent and outcome variables were further 
assessed using a linear regression model using log-transformed outcomes. 
The overall results of analysis showed that there is a significant difference 
between the long and short IVF treatment protocol and patient characteristics, such as 
age, education, religion, ethnicity, medical condition, and other variables such as drug 
used for down-regulation, duration of down-regulation, drug used for stimulation, and 
duration for stimulation. All influenced the number of oocytes. Details of findings are 
discussed in Chapter 5. 
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Chapter 5: Discussion, Conclusions, and Implications 
The findings from the results in Chapter 4 are explained in this chapter. The 
limitations of this study and the implications for future research in infertility treatment 
in Nigeria are also presented. 
Infertility treatment through IVF intervention has continued to advance 
worldwide with the view of reducing the burden, stigma, anxiety, emotional trauma, 
and economic losses that are associated with infertility (Okoroike, 2009). In Nigeria, 
IVF has gained popularity as a means to curb infertility problems as a result of 
increased awareness, demand, and increased number of fertility treatment centers, 
despite the relatively high cost of fertility treatment in Nigeria. 
Two IVF treatment protocols, long and short protocols, have been widely 
studied, but at the time of this study, such a study was never done in Nigeria to 
compare the outcome of both protocols. In this study, I have examined these protocols 
and patient characteristics, such as age, medical conditions (e.g., PCOS), SES, 
education, ethnicity, and other factors, like the number of gonadotropins used and 
duration of treatment and OHSS, using secondary data from 10 fertility centers across 
Nigeria. Descriptive and inferential statistical analysis was conducted on the data 
using SPSS Version 25 to establish the IVF treatment protocol most suitable for the 
majority of infertile women in Nigeria. 
At first, a standard distribution test on the outcome variable, which is 
continuous, using the histogram and density plot was conducted. The result showed a 
significant right skewness (Figure 1), depicting the nonnormal distribution of the 
outcome variable, hence the consideration for nonparametric test statistics. The 
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Wilcoxon rank-sum test was used to test the RQ1 null hypothesis of no relationships 
between treatment outcome in long and short treatment protocols. The result is as 
shown in the box plot (Figure 2). The median number of oocytes of the long and short 
protocol group were 8 and 4 to indicate a significant effect of the protocol group (W = 
54503, p < .001) on the number of oocytes. 
The RQ2 null hypothesis of no relationship between treatment outcome and 
patient characteristics, such as age, SES, ethnicity, religion, PCOS, and 
endometriosis, were inferentially tested using the statistics of a bivariate test. The 
figures for age and age group showed that age significantly affects treatment outcome 
of protocol group: r = −0.276 (95% CI −0.348, −0.200), p < .001, and the Kruskal-
Wallis, χ2(6) = 33.4796, p < .001. A statistically significant difference was also 
observed with the level of education and outcome of treatment in the groups, as 
indicated by the Kruskal-Wallis χ2(2) = 7.2751, p = .026. SES, tribe, religion, PCOS, 
and endometriosis showed similar results of significant difference in the groups 
(Figures 3, 4, 5, 6, 7, and 8), with the Kruskal-Wallis of χ2(2) = 15.1107, p < .001; the 
Kruskal-Wallis of χ2(3) = 13.1976, p < .001; the Kruskal-Wallis of  χ2(1) = 5.7181, 
p = .017; the Wilcoxon rank-sum of W = 56402, p < .001; and the Wilcoxon rank-sum 
of W = 52407, p < .001.  
Other factors, such as type of drug used for down-regulation, duration of 
down-regulation, type of drug used for stimulation, and duration of stimulation, were 
tested against treatment outcome of protocol group using bivariate statistical analysis, 
and the results were statistically significant (Figure 25), with the Kruskal-Wallis χ2 (2) 
= 76.1251, p < .001; drug for stimulation, the Pearson’s r = −.152 (95% CI −.229, 
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−.073), p < .001; dose of medication for stimulation, the Pearson’s r = −.152 (95% CI 
−.229, −.073), p < .001; and duration of stimulation, r = −.080 (−.001, −.159), p = 
.048. The entire result is summarized in Figures 26, 27, 28, and 30. 
The effect of confounding between the dependent and independent variables 
was also checked using bivariate analysis, and a linear regression model was used to 
examine the relationships between independent and dependent variables. The result 
showed that hospital factors accounted for 42.2% of the most effect on the outcome 
rather than types of protocol and patient characteristics. These results are reflected in 
Tables 4 and 6. 
Interpretation of Findings 
The dearth of studies on fertility treatment in Nigeria has made it necessary for 
findings from this study to be relevant to fertility clinicians and policymakers to 
reference this evidence-based outcome in their clinical decision related to which 
fertility treatment protocol should be considered for women seeking fertility treatment 
in Nigeria. 
In RQ1, I assessed a total of 605(N) fertility treatment folders of women 
between ages 20 and 54 (mean age 35.5) from 10 different hospitals across the six 
geo-political zones in Nigeria. I found that the median number of the oocyte is 8 and 4 
for long protocol and short protocol groups, respectively. The Wilcoxon rank-sum test 
showed that there is a significant effect of the protocol group (W = 54503, p < .001) 
on the number of oocytes. This finding is consistent with the study conducted by 
Jianping et al. (2015). They compared results of a GnRH analog in long and short 
treatment protocol groups of a 3-year data collection from 2010 to 2013, consisting of 
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5,662 (N) women of various ages, consisting of < 31 to > 40, who have completed 
IVF treatment cycle. Jianping et al. (2015) found that across all ages of participants, 
women who received long protocol treatment yielded higher and better quality 
oocytes than the women who had short protocol (p < 0.05). Likewise, Xiao et al. 
(2013) reported a higher number of and quality of oocyte follicles in the long protocol 
than in short protocol. 
In RQ2, I assessed to see if there is a relationship between patient 
characteristics and treatment outcomes in the two protocol groups. Age was the first 
characteristic examined against outcome using the Pearson correlation coefficient. 
The result showed a significant difference r = −0.276 (95% CI −0.348, −0.200), p < 
.001 (Figure 2). The age group was also examined against outcome using the Kruskal-
Wallis test statistics; the result was significant at χ2(6) = 33.4796, p < .001 (Figure 3). 
The result showed that the highest number of oocytes favored women of age < 30 
(median 10 and 8), and the oocyte number plateaued at age 30 to 39, after which the 
number of oocytes declined exponentially in both protocol groups as the age 
increased, which is consistent with the body’s natural physiological process.  
This finding is in agreement with retrospective studies by Faitt-Weller (2001) 
and Tan, Lau, Loh, and Tan (2014). They collected and analyzed 3,412 IVF treatment 
data from fertility hospitals between January 2008 to December 2010. The age of the 
women were in order of < 30 years, 30 to 35 years, 36 to 37 years, 38 years, 39 years, 
40 to 44 years, and > 45 years and the researchers discovered that age significantly 
affected the number of yielded oocyte, p < .001, and the highest number of oocytes 
were reported for women < 30 years (mean 18.5 +/- 10.3). Faitt-Weller (2001) also 
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stated that there is a decrease in the number of quality oocyte in IVF treatment as the 
age of the women increases. 
The level of education of women who had IVF treatment from the 10 fertility 
hospitals was considered as one of the patient characteristics. This was assessed using 
the Kruskal-Wallis inferential test statistics, and the result on the outcome of 
treatment was statistically significant at χ2(2) = 7.2751, p = .026. Women with tertiary 
education showed a better outcome than other women with a lower level of education 
(median 5). See Figure 4. This is likely because women with higher education were 
expected to present early for infertility treatment, with the understanding that delay 
may affect treatment outcome. Shruthi et al. (2014) conducted a 9-year, prospective 
cohort study with a sample size of 2,569, from 1994 to 2003, and using three fertility 
clinics in Boston. The influence of the educational level of women on IVF treatment 
outcome was assessed, and they found that women with a higher education level were 
able to follow the rules of the treatment protocol better than those with lower 
education (Shruthi et al., 2014). 
The SES was assessed among the patient characteristics that affect treatment 
outcome using the Kruskal-Wallis χ2(2) = 15.1107, p < .001 (Figure 5), showing a 
statistically significant association. In this case, women of low SES produced a higher 
number of oocytes (median 9) than women of medium and high SES class (median 5 
and 3), respectively. This finding is in contrast with the reports of Ho et al. (2017), 
who posited that women with higher income levels are more nourished and financially 
buoyant. They are more likely to present early at the clinic for fertility treatment, and 
they still do better with a higher yield of quality oocytes than those of lower-income.  
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Ethnicity is viewed as a prognostic factor in infertility (Dhillon et al. 2015; 
Maalouf, Campbell, & Jayaprakasan, 2017). Dhillon et al. (2015) investigated the 
relationship between ethnicity and IVF outcome, analyzing results of IVF cycles with 
a sample size of 13,473, comprised of different ethnicities (i.e., White, Black, and 
South Asian women), age, and BMI; the duration for infertility was adjusted. They 
compared their findings with 16 published meta-analysis results and reported that 
White women have better IVF oocytes and embryos than Black and South Asian 
women: Black versus White (OR 0.42 [0.25 to 0.70]; p = 0.001); South Asian versus 
White (OR 0.80 [0.65t o 0.99]; p = 0.04; Dhillon et al., 2015). In my study, the 
measure of the number of embryos and clinical pregnancy was a direct function of the 
number of oocytes; hence, a similar relationship between ethnicity and number of 
oocytes was established after the analysis of tribe (i.e., ethnicity) versus the number of 
oocytes. The Kruskal-Wallis of χ2(3) = 13.1976, p < .001 indicates a statistically 
significant relationship between the tribe and the outcome of the number of oocytes, 
with the Hausa women yielding a higher number of the oocyte (median 8) among the 
three major languages in Nigeria: Hausa, Ibo, and Yoruba. This finding is strongly 
associated with age. Hausa women practice early marriage; some marry at menarche 
and some as teenagers. A typical Hausa family is polygamous and Islamic, and Hausa 
women who had infertility sought help earlier than the other tribes. The Ibo and 
Yoruba women were next in that order (median 5 and 4); refer to Figure 6. 
Moreover, as observed in this study, religion showed a similar significant 
influence as an ethnicity on the number of oocytes (Figure 7). Islamic women had a 
higher number of oocytes (median 8) than Christian women (median 5), reflected by 
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the Kruskal-Wallis of χ2(1) = 5.7181, p = .017. This observation is unconnected to the 
belief that most Islamic women marry early, and those who have infertility issues 
sought early intervention. On the side of Christian women, they resort to prayers 
while waiting for the miraculous, and, as a result, most Christian women sought late 
intervention. McQuillan (2004) reported a similar fertility pattern, where he observed 
a higher fertility pattern amongst the Muslim women population than in the Christian 
women population worldwide. 
PCOS and endometriosis were also observed to affect the number of oocytes 
retrieved in these women significantly. The data showed that the women who had IVF 
treatment with no medical condition, such as PCOS, did better with the number of 
matured oocytes (median 8) than those with PCOS (median 3), with a Wilcoxon rank-
sum of W = 56402, p < .001. A similar trend was seen in women with no 
endometriosis, who did better with the number of matured oocytes (median 7) than 
those with endometriosis (median 4); the Wilcoxon rank-sum was W = 52407, p < 
.001, see also Figures 8 and 9. Similar findings were reported in a study by Hassani et 
al. (2019), where 60 women were used in a case-control study to assess the impact of 
PCOS on matured oocytes in IVF treatment. The result showed that women in the 
case group who had PCOS had a fewer number of matured oocytes than those in the 
control group who had no PCOS. Likewise, Senapati, Samuel, Morse, and Barnhart 
(2016) investigated and established the relationship between endometriosis and the 
number of matured oocytes yield. They analyzed the data of 347,185 IVF treatment 
cycles from 2008 to 2010 and reported that 11% of these women who had IVF 
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treatment were endometriotic patients, and the number of matured oocytes yielded 
was significantly lower in this group of women (Senapati et al, 2016). 
Other than these patient characteristics as discussed in this section, some 
factors such as a drug used for down-regulation, duration of down-regulation, the 
medicine used for stimulation, duration of stimulation, and dose of medication were 
also assessed to see if these factors impact on the number of oocytes yield in IVF 
treatment in both protocols.  
Results showed that Buserelin, a GnRHa, yielded a higher number of oocytes 
(median 8) than Cetrotide (median 5) and Zoladex (median 3), The Kruskal-Wallis of 
χ2(2) = 76.1251, p < .001 showed a statistically significant relationship between 
Drugs used for down-regulation and the outcome of the Number of oocytes. The 
duration of down-regulation was assessed, and I observed that a statistically 
significant relationship also exists between the Duration of downregulation in weeks 
and the outcome of the Number of oocytes. The Kruskal-Wallis, χ2(2) = 27.3558, p < 
.001, implies that the faster or shorter the response for optimum down-regulation, the 
better the number of oocytes, with results of 1-week down-regulation (median 8), 2-
week down-regulation (median 7), and 3-week down-regulation (median 4); see 
Figure 10. This finding indicates that women who took a longer time to achieve 
optimum down-regulation are more likely not to do better in the stimulation phase of 
IVF treatment and are regarded as the potential poor responders. 
The drugs used for stimulation were HMG, FSH, and a combination of the 
two. The impact of these drugs on the number of oocytes was assessed, and the result 
revealed that women who had HMG for stimulation did better (median 8) than those 
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who had FSH (median 5) and a combination of HMG and FSH (median 3); see Figure 
11. The Kruskal-Wallis of χ2(2) = 15.2588, p < .001 indicates a statistically 
significant relationship between Drugs used for stimulation and the outcome of the 
Number of oocytes. The length of stimulation against the number of oocytes was 
assessed using a Pearson correlation test statistics, and the result showed a weak 
positive outcome: r = −.080 (−.001, −.159), p = .048. This result pointed out that 
continuous stimulation after 10 days may not impact positively on the outcome. 
Findings from this study support the long protocol as the most favorable IVF 
treatment protocol for the majority of Nigeria infertile women, despite the cost, long 
duration of treatment, and other side effects that are tolerable. The findings from this 
study support the Patient-Centered Care Treatment Model framework in IVF 
treatment, which considers the peculiarity of a patient or group of patients in choosing 
which IVF treatment protocol would give a much-desired outcome. 
Limitations of the Study 
This study examined the IVF treatment protocols and the impact of patient 
characteristics on the number of oocytes. The study population was infertile Nigerian 
women. Only a few fertility hospitals are available in Nigeria, and these few hospitals 
are sparsely distributed, with most of them concentrated in Abuja, Federal Capital 
Territory. Hence, this study only captured the three major ethnic groups of Hausa, 
Ibo, and Yoruba women in Nigeria, with little consideration of other ethnic groups in 
Nigeria. Besides, very few fertility physicians are available in Nigeria, which 
probably accounts for the limited fertility hospitals in Nigeria. In the face of a large 
number of infertile women presenting for treatments, most physicians were in a hurry 
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and failed to capture some details that may have impacted the study outcome. As a 
result of pressure on the physician to start treatment by these women, most of the 
fertility physicians do not assess the patient to see which protocol is the best fit. 
Instead, treatment protocols are applied randomly. Moreover, some of the physicians 
use only one protocol for their patients for lack of experience with the other protocols. 
Recommendations 
The study showed that the median number of oocytes (median 8) generated 
following IVF treatment was more in the long protocol group than the median number 
of oocytes (median 5) in the short protocol group, and this difference was statistically 
significant. Likewise, the patient characteristics were also reported to have a 
statistically significant influence on the number of oocytes. Hence, the null 
hypotheses were not accepted. 
Though this study used existing secondary data not collected by the 
researcher; as such, some essential variables that could have impacted positively in 
this research were missing. Data such as cadre of fertility physician, medical officer 
or consultant, years of experience with fertility treatment, social lifestyle, previous 
IVF treatment, and such were not captured in folders. The effect of these variables on 
the outcome would have been studied. Hence, further study using a mixed-method to 
have more robust data on IVF treatment for analysis is recommended. 
There exist few fertility hospitals and fertility physicians in Nigeria, and most 
of these fertility centers are in Abuja, FCT. Training and re-training programs in 
infertility treatment are recommended to stir up interest in owners of hospitals and 
physicians in Nigeria to consider infertility treatment as a specialty. This way, there 
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would be more fertility centers across the country with a handful of expert physicians 
in this area of medical practice. 
Finally, according to the existing literature, my study is the first in Nigeria that 
has looked into the current protocol to see which is most favorable to Nigerian women 
who had IVF treatment. Hence, this study will form the baseline for future research 
into treatment protocols in Nigeria, though this could be an expensive adventure, as it 
would involve many hospitals and logistics. However, in the end, it would be a 
worthwhile adventure.  
The Implications for Social Change 
The social change implication of this study is that the research findings will 
assist practicing fertility specialists or intending specialists within or outside Nigeria 
to initiate treatment on an individual patient basis and the implications of deciding on 
which treatment protocol befits each who presents at the fertility clinic. Likewise, 
findings could be applied across a defined population with an understanding of 
treatment outcomes of the two protocols. These findings would provide evidence that 
could influence policies on guidelines for fertility treatment in Nigeria. 
The study findings showed that women with higher education did better with 
IVF treatment and that age is also a determinant of treatment outcome; women aged < 
35 did better than those women > 35 in this study. These findings could lead to a 
positive social change through a campaign program that focusses on (a) influencing 
women to seek improvement in their educational status for better living, (b) women 
empowerment through Government support or scholarship, and (c) early intervention 
to address delays in childbearing. The advocacy would educate women who wish to 
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delay marriage or child-bearing to pursue a carrier to consider the option of fertility 
preservation until a rightful time (Wada, 2015). 
Conclusion 
The number of women seeking help as a result of infertility has continued to 
rise in Nigeria, but with not enough fertility centers and requisite expertise to attend to 
this problem. Instead, many hospitals and physicians take advantage of the demand 
for infertility in Nigeria to offer care without being properly schooled: no hands-on 
experience in IVF procedure and stimulation or treatment protocols. Investigations 
have shown that the high level of treatment failure and chronic infertility experience 
leading to emotional and psychological distress in these women are the result of lack 
of experience in IVF procedure and the knowledge gap in the treatment protocol. 
Although infertility and its treatment protocols have been widely researched globally, 
in the Nigerian situation, no such study on IVF treatment protocol had been reported 
at the time of this research. 
The need to examine IVF treatment protocols has become imperative to find 
out which protocol is most favorable to Nigerian women receiving IVF treatment 
intervention. These findings can help practicing and interested physicians on which 
protocol would be most impactful to apply in any given situation. 
This study used existing fertility treatment data from 10 fertility hospitals 
across Nigeria, and the analysis of these data showed that of all the treatments 
assessed, the long fertility treatment protocol offered a more positive number of 
oocytes than the short protocol. Also, the further assessment showed that age, 
education, SES, religion, ethnicity, medical condition, a drug used for down-
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regulation, duration of down-regulation, the medication used for stimulation, and 
duration for stimulation were shown to influence treatment outcome. 
This finding will assist the fertility physicians in making an informed decision 
on which treatment protocol to consider for a patient or across a given defined 
population of infertile women seeking treatment. However, there is a need for 
continuous research in infertility in women, which could lead to the general 
improvement in reproductive health. 
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